<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86085</article-id><article-id pub-id-type="doi">10.7554/eLife.86085</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-304678"><name><surname>Hahn</surname><given-names>Lisa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0167-3947</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-295937"><name><surname>Eickhoff</surname><given-names>Simon B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6363-2759</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304679"><name><surname>Mueller</surname><given-names>Karsten</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-249535"><name><surname>Schilbach</surname><given-names>Leonhard</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304681"><name><surname>Barthel</surname><given-names>Henryk</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-259204"><name><surname>Fassbender</surname><given-names>Klaus</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3596-868X</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304682"><name><surname>Fliessbach</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304683"><name><surname>Kornhuber</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304684"><name><surname>Prudlo</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304685"><name><surname>Synofzik</surname><given-names>Matthis</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-204256"><name><surname>Wiltfang</surname><given-names>Jens</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-304686"><name><surname>Diehl-Schmid</surname><given-names>Janine</given-names></name><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author"><collab>FTLD Consortium</collab><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-317719"><name><surname>Otto</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-314594"><name><surname>Dukart</surname><given-names>Juergen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0492-5644</contrib-id><email>j.dukart@fz-juelich.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-304687"><name><surname>Schroeter</surname><given-names>Matthias L</given-names></name><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02nv7yv05</institution-id><institution>Institute of Neuroscience and Medicine, Brain &amp; Behaviour (INM-7), Research Centre Jülich</institution></institution-wrap><addr-line><named-content content-type="city">Jülich</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/024z2rq82</institution-id><institution>Institute of Systems Neuroscience, Medical Faculty, Heinrich Heine University Düsseldorf</institution></institution-wrap><addr-line><named-content content-type="city">Düsseldorf</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0387jng26</institution-id><institution>Max Planck Institute for Human Cognitive and Brain Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Leipzig</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution>LVR-Klinikum Düsseldorf</institution><addr-line><named-content content-type="city">Düsseldorf</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05591te55</institution-id><institution>Medical Faculty, Ludwig-Maximilians-Universität</institution></institution-wrap><addr-line><named-content content-type="city">München</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028hv5492</institution-id><institution>Department for Nuclear Medicine, University Hospital Leipzig</institution></institution-wrap><addr-line><named-content content-type="city">Leipzig</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01jdpyv68</institution-id><institution>Department of Neurology, Saarland University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Homburg</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xnwqx93</institution-id><institution>Department of Psychiatry and Psychotherapy, University Hospital Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043j0f473</institution-id><institution>German Center for Neurodegenerative Diseases (DZNE)</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0030f2a11</institution-id><institution>Department of Psychiatry and Psychotherapy, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg</institution></institution-wrap><addr-line><named-content content-type="city">Erlangen</named-content></addr-line><country>Germany</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04dm1cm79</institution-id><institution>Department of Neurology, University Medicine Rostock</institution></institution-wrap><addr-line><named-content content-type="city">Rostock</named-content></addr-line><country>Germany</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04zzwzx41</institution-id><institution>Department of Neurodegenerative Diseases, Center of Neurology, Hertie Institute for Clinical Brain Research</institution></institution-wrap><addr-line><named-content content-type="city">Tübingen</named-content></addr-line><country>Germany</country></aff><aff id="aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021ft0n22</institution-id><institution>Department of Psychiatry and Psychotherapy, University Medical Center Göttingen (UMG), Medical University Göttingen</institution></institution-wrap><addr-line><named-content content-type="city">Göttingen</named-content></addr-line><country>Germany</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00nt41z93</institution-id><institution>Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro</institution></institution-wrap><addr-line><named-content content-type="city">Aveiro</named-content></addr-line><country>Portugal</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02kkvpp62</institution-id><institution>Department of Psychiatry and Psychotherapy, Technical University of Munich</institution></institution-wrap><addr-line><named-content content-type="city">Munich</named-content></addr-line><country>Germany</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02sk64d67</institution-id><institution>kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic Medicine, Geriatrics and Neurology</institution></institution-wrap><addr-line><named-content content-type="city">Wasserburg/Inn</named-content></addr-line><country>Germany</country></aff><aff id="aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032000t02</institution-id><institution>Department of Neurology, Ulm University</institution></institution-wrap><addr-line><named-content content-type="city">Ulm</named-content></addr-line><country>Germany</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gqaka33</institution-id><institution>Department of Neurology, Martin-Luther-University Halle-Wittenberg</institution></institution-wrap><addr-line><named-content content-type="city">Halle</named-content></addr-line><country>Germany</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0387jng26</institution-id><institution>Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences</institution></institution-wrap><addr-line><named-content content-type="city">Leipzig</named-content></addr-line><country>Germany</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/028hv5492</institution-id><institution>Clinic for Cognitive Neurology, University Hospital Leipzig</institution></institution-wrap><addr-line><named-content content-type="city">Leipzig</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>15</day><month>01</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>13</volume><elocation-id>e86085</elocation-id><history><date date-type="received" iso-8601-date="2023-01-10"><day>10</day><month>01</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-14"><day>14</day><month>12</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-09-01"><day>01</day><month>09</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.30.22278624"/></event></pub-history><permissions><copyright-statement>© 2024, Hahn et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Hahn et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86085-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-86085-figures-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Aside to clinical changes, behavioral variant frontotemporal dementia (bvFTD) is characterized by progressive structural and functional alterations in frontal and temporal regions. We examined if there is a selective vulnerability of specific neurotransmitter systems in bvFTD by evaluating the link between disease-related functional alterations and the spatial distribution of specific neurotransmitter systems and their underlying gene expression levels.</p></sec><sec id="abs2"><title>Methods:</title><p>Maps of fractional amplitude of low-frequency fluctuations (fALFF) were derived as a measure of local activity from resting-state functional magnetic resonance imaging for 52 bvFTD patients (mean age = 61.5 ± 10.0 years; 14 females) and 22 healthy controls (HC) (mean age = 63.6 ± 11.9 years; 13 females). We tested if alterations of fALFF in patients co-localize with the non-pathological distribution of specific neurotransmitter systems and their coding mRNA gene expression. Furthermore, we evaluated if the strength of co-localization is associated with the observed clinical symptoms.</p></sec><sec id="abs3"><title>Results:</title><p>Patients displayed significantly reduced fALFF in frontotemporal and frontoparietal regions. These alterations co-localized with the distribution of serotonin (5-HT1b and 5-HT2a) and γ-aminobutyric acid type A (GABAa) receptors, the norepinephrine transporter (NET), and their encoding mRNA gene expression. The strength of co-localization with NET was associated with cognitive symptoms and disease severity of bvFTD.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Local brain functional activity reductions in bvFTD followed the distribution of specific neurotransmitter systems indicating a selective vulnerability. These findings provide novel insight into the disease mechanisms underlying functional alterations. Our data-driven method opens the road to generate new hypotheses for pharmacological interventions in neurodegenerative diseases even beyond bvFTD.</p></sec><sec id="abs5"><title>Funding:</title><p>This study has been supported by the German Consortium for Frontotemporal Lobar Degeneration, funded by the German Federal Ministry of Education and Research (BMBF; grant no. FKZ01GI1007A).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>frontotemporal dementia</kwd><kwd>neurodegeneration</kwd><kwd>resting-state fMRI</kwd><kwd>selective vulnerability</kwd><kwd>monoamines</kwd><kwd>GABA</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002347</institution-id><institution>Bundesministerium für Bildung und Forschung</institution></institution-wrap></funding-source><award-id>FKZ01GI1007A</award-id><principal-award-recipient><name><surname>Mueller</surname><given-names>Karsten</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SCHR 774/5-1</award-id><principal-award-recipient><name><surname>Schroeter</surname><given-names>Matthias L</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006298</institution-id><institution>Sächsische Aufbaubank</institution></institution-wrap></funding-source><award-id>eHealthSax Initiative</award-id><principal-award-recipient><name><surname>Schroeter</surname><given-names>Matthias L</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020 - Research and Innovation Framework Programme</institution></institution-wrap></funding-source><award-id>TheVirtualBrain-Cloud 826421</award-id><principal-award-recipient><name><surname>Dukart</surname><given-names>Juergen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013278</institution-id><institution>EU Joint Programme – Neurodegenerative Disease Research</institution></institution-wrap></funding-source><award-id>GENFI-prox</award-id><principal-award-recipient><name><surname>Otto</surname><given-names>Markus</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Local brain functional activity reductions in bvFTD follow the distribution of serotonergic, GABAergic, and norepinephrinergic neurotransmitter systems, indicating a selective vulnerability and providing novel insights into the underlying disease mechanisms.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Frontotemporal lobar degeneration is the second most common type of early-onset dementia under the age of 65 years (<xref ref-type="bibr" rid="bib22">Harvey et al., 2003</xref>). Its most common subtype, behavioral variant frontotemporal dementia (bvFTD), is characterized by detrimental changes in personality and behavior (<xref ref-type="bibr" rid="bib45">Pressman and Miller, 2014</xref>). Patients can display both apathy and disinhibition, often combined with a lack of insight, and executive and socioemotional deficits (<xref ref-type="bibr" rid="bib53">Schroeter et al., 2011</xref>; <xref ref-type="bibr" rid="bib54">Schroeter et al., 2012</xref>). Despite striking and early symptoms, bvFTD patients are often (i.e. up to 50%) misdiagnosed as having a psychiatric illness rather than a neurodegenerative disease (<xref ref-type="bibr" rid="bib65">Woolley et al., 2011</xref>).</p><p>In addition to the presence of symptoms, the diagnosis requires consideration of family history due to its frequent heritable component and examination of different neuroimaging modalities (<xref ref-type="bibr" rid="bib45">Pressman and Miller, 2014</xref>; <xref ref-type="bibr" rid="bib3">Bang et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Schroeter et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Schroeter et al., 2008</xref>). Whereas atrophy in frontoinsular areas only occurs in later disease stages, glucose hypometabolism in frontal, anterior cingulate, and anterior temporal regions visible with fluorodeoxyglucose positron emission tomography (FDG-PET) is already detectable from an early stage onwards (<xref ref-type="bibr" rid="bib3">Bang et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Diehl-Schmid et al., 2007</xref>). The fractional amplitude of low-frequency fluctuations (fALFF) is a resting-state functional magnetic resonance imaging (rsfMRI) derived measure with good test–retest reliability that closely correlates with FDG-PET (<xref ref-type="bibr" rid="bib2">Aiello et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Holiga et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">Deng et al., 2022</xref>). In frontotemporal dementia (FTD) patients, fALFF was reduced in inferior parietal, frontal lobes, and posterior cingulate cortex and holds great potential as MRI biomarker (<xref ref-type="bibr" rid="bib44">Premi et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Borroni et al., 2018</xref>). Low local fALFF activity in the left insula was linked to symptom deterioration (<xref ref-type="bibr" rid="bib6">Day et al., 2013</xref>).</p><p>On a molecular level, frontotemporal lobar degeneration can be differentiated into three different subtypes based on abnormal protein deposition: tau (tau protein), transactive response DNA-binding protein with molecular weight 43 kDa (TDP-43), and FET (fused-in-sarcoma [FUS] and Ewing sarcoma [EWS] proteins, and TATA-binding protein-associated factor 15 [TAF15]) (<xref ref-type="bibr" rid="bib3">Bang et al., 2015</xref>; <xref ref-type="bibr" rid="bib19">Haass and Neumann, 2016</xref>). Whereas tau and TDP pathologies each occur in half of the bvFTD patients, FUS pathology is very rare (<xref ref-type="bibr" rid="bib64">Whitwell et al., 2011</xref>). Several possible mechanisms are discussed in the literature for the spread of these proteins throughout the brain, from a selective neuronal vulnerability (i.e. specific neurons being inherently more susceptible to the underlying disease-related mechanisms) to prion-like propagation of the respective proteins (<xref ref-type="bibr" rid="bib63">Walsh and Selkoe, 2016</xref>; <xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>). The latter entails that misfolded proteins accumulate and induce a self-perpetuating process so that protein aggregates can spread and amplify, leading to gradual dysfunction and eventually death of neurons and glial cells (<xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>). For example, tau can cause presynaptic dysfunction prior to loss of function or cell death (<xref ref-type="bibr" rid="bib68">Zhou et al., 2017</xref>), whereas overexpression of TDP-43 leads to impairment of presynaptic integrity (<xref ref-type="bibr" rid="bib25">Heyburn and Moussa, 2016</xref>). The role of FET proteins is not fully understood, although their involvement in gene expression suggests a mechanism of altered RNA processing (<xref ref-type="bibr" rid="bib60">Svetoni et al., 2016</xref>).</p><p>Neuronal connectivity plays a key role in the spread of pathology as it is thought to transmit along neural networks. Supporting the notion, previous studies also found an association between tau levels and functional connectivity in functionally connected brain regions, for example across normal aging and Alzheimer’s disease (<xref ref-type="bibr" rid="bib15">Franzmeier et al., 2019</xref>). Thereby, dopaminergic, serotonergic, glutamatergic, and GABAergic neurotransmission is affected. More specifically, current research indicates a deficit of neurons and receptors in these neurotransmitter systems (<xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>; <xref ref-type="bibr" rid="bib29">Huey et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Murley and Rowe, 2018</xref>). Furthermore, these deficits have been associated with clinical symptoms. For example, whereas GABAergic deficits have been associated with disinhibition, increased dopaminergic neurotransmission and altered serotonergic modulation of dopaminergic neurotransmission have been associated with agitated and aggressive behavior (<xref ref-type="bibr" rid="bib14">Engelborghs et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Murley et al., 2020</xref>). Another study related apathy to glucose hypometabolism in the ventral tegmental area, a hub of the dopaminergic network (<xref ref-type="bibr" rid="bib53">Schroeter et al., 2011</xref>). Despite this compelling evidence of disease-related impairment at functional and molecular levels, the relationship between both remains poorly understood. It also remains unknown if the above neurotransmitter alterations reflect a disease-specific vulnerability of specific neuron populations or merely reflect a consequence of the ongoing neurodegeneration.</p><p>Based on the above findings, we hypothesize that the spatial distribution of fALFF and gray matter (GM) pathology in FTD will be related to the distribution of dopaminergic, serotonergic, and GABAergic neurotransmission. The aim of the current study was to gain novel insight into the disease mechanisms underlying functional and structural alterations in bvFTD by examining if there is a selective vulnerability of specific neurotransmitter systems. We evaluated the link between disease-related functional alterations and the spatial distribution of specific neurotransmitter systems and their underlying gene expression levels. In addition, we tested if these associations are linked to specific symptoms observed in this clinical population.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Subjects</title><p>We included 52 Caucasian patients with bvFTD (mean age = 61.5 ± 10.0 years; 14 females) and 22 Caucasian age-matched healthy controls (HC) (mean age = 63.6 ± 11.9 years; 13 females) examined in nine centers of the German Consortium for Frontotemporal Lobar Degeneration (<ext-link ext-link-type="uri" xlink:href="http://www.ftld.de">http://www.ftld.de</ext-link>; <xref ref-type="bibr" rid="bib41">Otto et al., 2011</xref>) into this study. Details regarding the distribution of demographic characteristics across centers are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>. Diagnosis was based on established international diagnostic criteria (<xref ref-type="bibr" rid="bib46">Rascovsky et al., 2011</xref>). Written informed consent was collected from each participant. The study was approved by the ethics committees of all universities involved in the German Consortium for Frontotemporal Lobar Degeneration (Ethics Committee University of Ulm approval number 20/10) and was in accordance with the latest version of the Declaration of Helsinki. The clinical and neuropsychological test data included the Mini Mental State Exam (MMSE), Verbal Fluency (VF; animals), Boston Naming Test (BNT), Trail Making Test B (TMT-B), Apathy Evaluation Scale (AES) (companion-rated) (<xref ref-type="bibr" rid="bib17">Glenn, 2005</xref>), Frontal Systems Behavior Scale (FrSBe) (companion-rated) incl. subscales (executive function [EF], inhibition, and apathy) (<xref ref-type="bibr" rid="bib18">Grace and Malloy, 2001</xref>), and Clinical Dementia Rating-Frontotemporal Lobar Degeneration scale‐modified (CDR-FTLD) (<xref ref-type="bibr" rid="bib33">Knopman et al., 2008</xref>). Demographic and neuropsychological test information for both groups is displayed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Demographic and clinical information for bvFTD patients and HC.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="2">bvFTD</th><th align="left" valign="bottom" colspan="2">HC</th><th align="left" valign="bottom" colspan="2">Group comparison</th></tr></thead><tbody><tr><td align="left" valign="bottom">Age (years)</td><td align="left" valign="bottom">61.5 ± 10.0</td><td align="left" valign="bottom"><italic>N</italic> = 52</td><td align="left" valign="bottom">63.6 ± 11.9</td><td align="left" valign="bottom"><italic>N</italic> = 22</td><td align="left" valign="bottom"><italic>t</italic> = −0.78</td><td align="left" valign="bottom">p = 0.44</td></tr><tr><td align="left" valign="bottom">Sex (male/female)</td><td align="left" valign="bottom">38/14</td><td align="left" valign="bottom"><italic>N</italic> = 52</td><td align="left" valign="bottom">9/13</td><td align="left" valign="bottom"><italic>N</italic> = 22</td><td align="left" valign="bottom"><italic>Χ</italic>² = 6.90</td><td align="left" valign="bottom">p = 0.009<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Education (years)</td><td align="left" valign="bottom">13.7 ± 3.19</td><td align="left" valign="bottom"><italic>N</italic> = 50</td><td align="left" valign="bottom">13.5 ± 2.56</td><td align="left" valign="bottom"><italic>N</italic> = 22</td><td align="left" valign="bottom"><italic>t</italic> = 0.21</td><td align="left" valign="bottom">p = 0.84</td></tr><tr><td align="left" valign="bottom">Disease duration (years)</td><td align="left" valign="bottom">3.98 ± 5.22</td><td align="left" valign="bottom"><italic>N</italic> = 49</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom">–</td><td align="left" valign="bottom">–</td></tr><tr><td align="left" valign="bottom">Verbal Fluency (number of animals)</td><td align="left" valign="bottom">12.2 ± 6.48</td><td align="left" valign="bottom"><italic>N</italic> = 49</td><td align="left" valign="bottom">27.5 ± 4.77</td><td align="left" valign="bottom"><italic>N</italic> = 19</td><td align="left" valign="bottom"><italic>t</italic> = −9.30</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Boston Naming Test (total score)</td><td align="left" valign="bottom">12.9 ± 2.79</td><td align="left" valign="bottom"><italic>N</italic> = 49</td><td align="left" valign="bottom">15.0 ± 0.22</td><td align="left" valign="bottom"><italic>N</italic> = 20</td><td align="left" valign="bottom"><italic>t</italic> = −3.28</td><td align="left" valign="bottom">p = 0.002<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Mini Mental State Exam (total score)</td><td align="left" valign="bottom">25.2 ± 4.48</td><td align="left" valign="bottom"><italic>N</italic> = 50</td><td align="left" valign="bottom">29.3 ± 0.64</td><td align="left" valign="bottom"><italic>N</italic> = 20</td><td align="left" valign="bottom"><italic>t</italic> = −4.03</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Trail Making Test B (s)</td><td align="left" valign="bottom">179 ± 84.4</td><td align="left" valign="bottom"><italic>N</italic> = 36</td><td align="left" valign="bottom">78.5 ± 22.0</td><td align="left" valign="bottom"><italic>N</italic> = 19</td><td align="left" valign="bottom"><italic>t</italic> = 5.09</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Apathy Evaluation Scale (total score)</td><td align="left" valign="bottom">32.7 ± 11.0</td><td align="left" valign="bottom"><italic>N</italic> = 35</td><td align="left" valign="bottom">9.50 ± 5.26</td><td align="left" valign="bottom"><italic>N</italic> = 4</td><td align="left" valign="bottom"><italic>t</italic> = 4.13</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Frontal Systems Behavior Scale<break/>(companion-rated, total frequency)</td><td align="left" valign="bottom">72.7 ± 16.1</td><td align="left" valign="bottom"><italic>N</italic> = 34</td><td align="left" valign="bottom">38.8 ± 12.3</td><td align="left" valign="bottom"><italic>N</italic> = 5</td><td align="left" valign="bottom"><italic>t</italic> = 4.49</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Frontal Systems Behavior Scale<break/>(companion-rated, total distress)</td><td align="left" valign="bottom">66.9 ± 21.0</td><td align="left" valign="bottom"><italic>N</italic> = 29</td><td align="left" valign="bottom">32 ± 9.56</td><td align="left" valign="bottom"><italic>N</italic> = 4</td><td align="left" valign="bottom"><italic>t</italic> = 3.25</td><td align="left" valign="bottom">p = 0.003<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Frontal Systems Behavior Scale: Executive Function<break/>(companion-rated, total distress)</td><td align="left" valign="bottom">23.6 ± 7.39</td><td align="left" valign="bottom"><italic>N</italic> = 34</td><td align="left" valign="bottom">11.8 ± 4.50</td><td align="left" valign="bottom"><italic>N</italic> = 4</td><td align="left" valign="bottom"><italic>t</italic> = 3.11</td><td align="left" valign="bottom">p = 0.004<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr><tr><td align="left" valign="bottom">Clinical Dementia Rating-Frontotemporal Lobar Degeneration (total score)</td><td align="left" valign="bottom">8.06 ± 3.92</td><td align="left" valign="bottom"><italic>N</italic> = 45</td><td align="left" valign="bottom">0.05 ± 0.16</td><td align="left" valign="bottom"><italic>N</italic> = 19</td><td align="left" valign="bottom"><italic>t</italic> = 5.07</td><td align="left" valign="bottom">p &lt; 0.001<xref ref-type="table-fn" rid="table1fn2">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p>bvFTD – behavioral variant frontotemporal dementia, HC – healthy controls.</p></fn><fn id="table1fn2"><label>*</label><p>Significant at p &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>MRI acquisition and preprocessing of imaging data</title><p>Structural T1-weighted magnetization-prepared rapid gradient-echo MRI and rsfMRI (TR = 2000 ms, TE = 30 ms, FOV = 64 × 64 × 30, voxel size = 3 × 3 × 5 mm, 300 volumes) were acquired on 3T devices. <xref ref-type="table" rid="table2">Table 2</xref> reports center-specific imaging parameters confirming a high level of harmonization.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Center-specific imaging parameters for structural and functional imaging.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Center</th><th align="left" valign="bottom" colspan="5">rsfMRI</th><th align="left" valign="bottom" colspan="4">Structural MRI</th></tr><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">TE (ms)</th><th align="left" valign="bottom">TR (ms)</th><th align="left" valign="bottom">FOV(<italic>X</italic>, <italic>Y</italic>, <italic>Z</italic>)</th><th align="left" valign="bottom">Voxel size (mm)</th><th align="left" valign="bottom">Volumes</th><th align="left" valign="bottom">TE (ms)</th><th align="left" valign="bottom">TR (ms)</th><th align="left" valign="bottom">FOV(<italic>X</italic>, <italic>Y</italic>, <italic>Z</italic>)</th><th align="left" valign="bottom">Voxel size (mm)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Bonn</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">3.06</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Erlangen</td><td align="char" char="." valign="bottom">34</td><td align="char" char="." valign="bottom">3000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.98</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Göttingen</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 6</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.96</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">256 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Homburg</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.98</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Leipzig</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.98</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">München (TU)</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 x 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.98</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Rostock</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2200</td><td align="left" valign="bottom">64 × 64 × 34</td><td align="left" valign="bottom">3.5 × 3.5 × 3.5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">4.82</td><td align="char" char="." valign="bottom">2500</td><td align="left" valign="bottom">256 × 256 × 192</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Tübingen</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.96</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 176</td><td align="left" valign="bottom">1 × 1 × 1</td></tr><tr><td align="left" valign="bottom">Ulm</td><td align="char" char="." valign="bottom">30</td><td align="char" char="." valign="bottom">2000</td><td align="left" valign="bottom">64 × 64 × 30</td><td align="left" valign="bottom">3 × 3 × 5</td><td align="char" char="." valign="bottom">300</td><td align="char" char="." valign="bottom">2.05</td><td align="char" char="." valign="bottom">2300</td><td align="left" valign="bottom">240 × 256 × 192</td><td align="left" valign="bottom">1 × 1 × 1</td></tr></tbody></table><table-wrap-foot><fn><p>rsfMRI – resting-state functional magnetic resonance imaging, MRI – magnetic resonance imaging, TE – echo time, TR – repetition time, FOV – field of view.</p></fn><fn><p>Bonn – University of Bonn, German Center for Neurodegenerative Diseases (DZNE), University Hospital Bonn.</p></fn><fn><p>Erlangen – University Hospital Erlangen.</p></fn><fn><p>Göttingen – Medical University Göttingen.</p></fn><fn><p>Homburg – Saarland University Hospital.</p></fn><fn><p>Leipzig – Max-Planck-Institute for Human Cognitive and Brain Sciences.</p></fn><fn><p>TU München – Technical University of Munich.</p></fn><fn><p>Rostock – University Hospital Rostock, German Center for Neurodegenerative Diseases (DZNE).</p></fn><fn><p>Tübingen – University Hospital Tübingen, Centre for Neurology, Hertie-Institute for Clinical Brain Research.</p></fn><fn><p>Ulm – Ulm University.</p></fn></table-wrap-foot></table-wrap><p>All initial preprocessing of imaging data was performed using SPM12 (<xref ref-type="bibr" rid="bib42">Penny et al., 2011</xref>). To calculate voxel-wise GM volume (GMV), structural images were segmented, spatially normalized to MNI space, modulated, and smoothed by a Gaussian convolution kernel with 6 mm full-width at half maximum (FWHM). RsfMRI images were realigned, unwarped, co-registered to the structural image, spatially normalized to MNI space, and smoothed with a Gaussian convolution kernel with 6 mm FWHM. A GM mask was applied to reduce all analyses to GM tissue. Images were further processed in the REST toolbox (<xref ref-type="bibr" rid="bib59">Song et al., 2011</xref>) version 1.8. Mean white matter and cerebrospinal fluid signals as wells as 24 motion parameters (Friston-24) were regressed out before computing voxel-based measures of interest. fALFF was calculated at each voxel as the root mean square of the blood oxygen level-dependent signal amplitude in the analysis frequency band (here: 0.01–0.08 Hz) divided by the amplitude in the entire frequency band (<xref ref-type="bibr" rid="bib59">Song et al., 2011</xref>). fALFF is closely linked to FDG-PET and other measures of local metabolic activity as has been shown in healthy participants but also for example in Alzheimer’s disease (<xref ref-type="bibr" rid="bib7">Deng et al., 2022</xref>; <xref ref-type="bibr" rid="bib36">Marchitelli et al., 2018</xref>).</p></sec><sec id="s2-3"><title>Contrast analyses of fALFF and GMV</title><p>To test for fALFF alterations, group comparisons were performed in SPM12 using a flexible-factorial design with group (bvFTD or HC) as a factor and age, sex, and site (i.e. one dummy variable per site) as covariates (<xref ref-type="bibr" rid="bib30">Huotari et al., 2019</xref>). To test for group differences in GMV, the same design with addition of total intracranial volume (TIV) was used. Pairwise group <italic>t</italic>-contrasts (i.e. HC &gt; bvFTD, bvFTD &gt; HC) were evaluated for significance using an exact permutation-based cluster threshold (1000 permutations permuting group labels, p &lt; 0.05) to control for multiple comparisons combined with an uncorrected voxel-threshold of p &lt; 0.001. A permutation-based cluster threshold combined with an uncorrected voxel-threshold was used since standard correction methods such as a family wise error rate of 5% may lead to elevated false-positive rates (<xref ref-type="bibr" rid="bib13">Eklund et al., 2016</xref>).</p></sec><sec id="s2-4"><title>Spatial correlation with neurotransmitter density maps</title><p>Confounding effects of age, sex, and site were regressed out from all images prior to further spatial correlation analyses. To test if fALFF alterations in bvFTD patients (relative to HC) are correlated with specific neurotransmitter systems, the JuSpace toolbox (<xref ref-type="bibr" rid="bib12">Dukart et al., 2021</xref>) was used. The JuSpace toolbox allows for cross-modal spatial correlations of different neuroimaging modalities with nuclear imaging derived information about the relative density distribution of various neurotransmitter systems. All neurotransmitter maps were derived as averages from an independent healthy volunteer population and processed as described in the JuSpace publication including rescaling and normalization into the Montreal Neurological Institute space. More specifically, we wanted to test if the spatial structure of fALFF maps in patients relative to HC is similar to the distribution of nuclear imaging derived neurotransmitter maps from independent healthy volunteer populations included in the toolbox (5-HT1a receptor [<xref ref-type="bibr" rid="bib51">Savli et al., 2012</xref>], 5-HT1b receptor [<xref ref-type="bibr" rid="bib51">Savli et al., 2012</xref>], 5-HT2a receptor [<xref ref-type="bibr" rid="bib51">Savli et al., 2012</xref>], serotonin transporter [5-HTT; <xref ref-type="bibr" rid="bib51">Savli et al., 2012</xref>], D1 receptor [<xref ref-type="bibr" rid="bib32">Kaller et al., 2017</xref>], D2 receptor [<xref ref-type="bibr" rid="bib50">Sandiego et al., 2015</xref>], dopamine transporter [DAT; <xref ref-type="bibr" rid="bib11">Dukart et al., 2018</xref>], Fluorodopa [FDOPA; <xref ref-type="bibr" rid="bib16">García Gómez et al., 2018</xref>], γ-aminobutyric acid type A [GABAa] receptors [<xref ref-type="bibr" rid="bib11">Dukart et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Myers et al., 2012</xref>], μ-opioid [MU] receptors [<xref ref-type="bibr" rid="bib1">Aghourian et al., 2017</xref>], and norepinephrine transporter [NET; <xref ref-type="bibr" rid="bib24">Hesse et al., 2017</xref>]). Detailed information about the publicly available neurotransmitter maps is provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>. In contrast to standard analyses of fMRI data, this analysis might provide novel insight into potential neurophysiological mechanisms underlying the observed correlations (<xref ref-type="bibr" rid="bib12">Dukart et al., 2021</xref>). Using the toolbox, mean values were extracted from both neurotransmitter and fALFF maps using GM regions from the Neuromorphometrics atlas. Extracted mean regional values of the patients’ fALFF maps were <italic>z</italic>-transformed relative to HC. Spearman correlation coefficients (Fisher’s <italic>z</italic>-transformed) were calculated between these <italic>z</italic>-transformed fALFF maps of the patients and the spatial distribution of the respective neurotransmitter maps. Exact permutation-based p-values as implemented in JuSpace (10,000 permutations randomly assigning group labels using orthogonal permutations) were computed to test if the distribution of the observed Fisher’s <italic>z</italic>-transformed individual correlation coefficients significantly deviated from zero. Furthermore, adjustment for spatial autocorrelation was performed by computing partial correlation coefficients between fALFF and neurotransmitter maps adjusted for local GM probabilities estimated from the SPM12-provided TPM.nii (<xref ref-type="bibr" rid="bib12">Dukart et al., 2021</xref>). All analyses were false discovery rate (FDR) corrected for the number of tests (i.e. the number of neurotransmitter maps). To further test if and how the observed fALFF co-localization patterns are explained by the underlying global atrophy, we repeated the co-localization analysis (p &lt; 0.05) for the significant fALFF–neurotransmitter associations after controlling for total GMV. Additionally, the receiver operating characteristic (ROC) curves and corresponding areas under the curve (AUC) were calculated for patients (Fisher’s <italic>z</italic>-transformed Spearman correlations) vs. HC (leave-one-out <italic>Z</italic>-score maps) to examine discriminability of the resulting fALFF–neurotransmitter correlations.</p></sec><sec id="s2-5"><title>Correlation with structural data</title><p>To test if the significant correlations observed between fALFF and neurotransmitter maps were driven by structural alterations (i.e. partial volume effects), the JuSpace analysis using the same parameters was repeated with local GMV incl. a correction for confounding effects of age, sex, site, and TIV. For further exploration, fALFF and GMV Fisher’s <italic>z</italic>-transformed Spearman correlations as computed by the JuSpace toolbox were correlated with each other for each patient over all neurotransmitters. The median of those correlation coefficients was squared to calculate the variance in fALFF explained by GMV.</p></sec><sec id="s2-6"><title>Correlation with clinical data</title><p>To test if fALFF–neurotransmitter correlations are related to symptoms of bvFTD, we calculated Spearman correlation coefficients between significant fALFF–neurotransmitter correlations (Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients from JuSpace toolbox output) and clinical scales and neuropsychological test data (see <xref ref-type="table" rid="table1">Table 1</xref>). All analyses were FDR corrected for the number of tests. In addition, to test for the specificity of these associations we examined the direct associations between fALFF and the neuropsychological tests by computing Spearman correlations with the Eigenvariates extracted from the largest cluster of the HC &gt; bvFTD SPM contrast.</p></sec><sec id="s2-7"><title>Association with gene expression profile maps</title><p>Furthermore, to test if fALFF alterations in bvFTD patients associated with specific neurotransmitter systems in the JuSpace analysis were also spatially correlated with their underlying mRNA gene expression profile maps, the MENGA toolbox (<xref ref-type="bibr" rid="bib49">Rizzo et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Rizzo et al., 2014</xref>) was used. <italic>Z</italic>-scores were calculated for the patients relative to HC using the confound-corrected images. The analyses were performed using 169 regions of interest and genes corresponding to each significantly associated neurotransmitter from the JuSpace analysis (5-HT1b: <italic>HTR1B</italic>; 5-HT2a: <italic>HTR2A</italic>; GABAa (19 subunits): <italic>GABRA1–6</italic>, <italic>GABRB1–3</italic>, <italic>GABRG1–3</italic>, <italic>GABRR1–3</italic>, <italic>GABRD</italic>, <italic>GABRE</italic>, <italic>GABRP</italic>, <italic>GABRQ</italic>; NET: <italic>SLC6A2</italic>). More specifically, Spearman correlation coefficients were calculated between the genomic values and re-sampled image values in the regions of interest for each patient and for each mRNA donor from the Allen Brain Atlas (<xref ref-type="bibr" rid="bib23">Hawrylycz et al., 2012</xref>) separately. The Fisher’s <italic>z</italic>-transformed correlation coefficients were averaged over the six mRNA donors. Bonferroni-corrected one-sample <italic>t</italic>-tests were performed for each neurotransmitter to examine, whether the correlation coefficient differed significantly from zero.</p></sec><sec id="s2-8"><title>Neurotransmitter-genomic correlations and gene differential stability</title><p>To further examine the association of fALFF–neurotransmitter correlations and mRNA gene expression profile maps, we explored the relationship between neurotransmitter maps included in the JuSpace toolbox and mRNA maps provided in the MENGA toolbox. The MENGA analysis was repeated using the same parameters to obtain Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients between the neurotransmitter maps and the mRNA gene expression profile maps.</p><p>To evaluate the robustness of the mRNA maps between donors, gene differential stability was estimated by computing the Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients between the genomic values of each of the six mRNA donors, which were then averaged (<xref ref-type="bibr" rid="bib23">Hawrylycz et al., 2012</xref>).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Contrast analysis of fALFF and GMV</title><p>First, we tested for group differences in fALFF between HC and patients. Compared to HC, bvFTD patients showed a significantly reduced fALFF signal in frontoparietal and frontotemporal regions (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Furthermore, patients also showed reduced GMV in medial and lateral prefrontal, insular, temporal, anterior caudate, and thalamic regions in comparison to HC (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). For a detailed representation of the thresholded fALFF and GMV t-maps, see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Cluster size, peak-level MNI coordinates, and corresponding anatomical regions incl. the additional fALFF analysis with correction for total GMV are reported in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>. For the distribution of Eigenvariates for the two groups in both modalities, see <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Voxel-wise results for fractional amplitude of low-frequency fluctuation (fALFF) and gray matter volume (GMV) group comparisons.</title><p>Thresholded fALFF t-map (<bold>A</bold>) and thresholded GMV t-map (<bold>B</bold>) for healthy control (HC; N = 22) &gt; behavioral variant frontotemporal dementia (bvFTD; N = 52) using a permutation-based threshold (1000 permutations permuting group labels) at cluster-level p &lt; 0.05 and voxel-level p &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Detailed voxel-wise results for fractional amplitude of low-frequency fluctuation (fALFF) and gray matter volume (GMV) group comparisons.</title><p>Thresholded fALFF t-map (<bold>A</bold>) and thresholded GMV t-map (<bold>B</bold>) for healthy control (HC; N = 22) &gt; behavioral variant frontotemporal dementia (bvFTD; N = 52) using a permutation-based threshold (1000 permutations permuting group labels) at cluster-level p &lt; 0.05 and voxel-level p &lt; 0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Eigenvariates from fractional amplitude of low-frequency fluctuation (fALFF) and gray matter volume (GMV) for behavioral variant frontotemporal dementia (bvFTD) patients and controls.</title><p>Eigenvariates were derived from the largest cluster in the healthy control (HC; N = 22) &gt; behavioral variant frontotemporal dementia (bvFTD; N = 52) contrasts for fALFF (<bold>A</bold>) and GMV (<bold>B</bold>). Means are represented by white circles.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1—figure supplement 2—source data 1.</label><caption><title>Eigenvariates of fractional amplitude of low-frequency fluctuation (fALFF) and gray matter volume (GMV) for largest clusters of healthy control (HC) &gt; behavioral variant frontotemporal dementia (bvFTD) <italic>t</italic>-contrasts shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86085-fig1-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig1-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s3-2"><title>Spatial correlation with neurotransmitter maps</title><p>We performed correlation analyses to test if fALFF alterations in bvFTD significantly co-localize with the spatial distribution of specific neurotransmitter systems. fALFF alterations in bvFTD as compared to HC were significantly associated with the spatial distribution of 5-HT1b (mean <italic>r</italic> = −0.21, p &lt; 0.001), 5-HT2a (mean <italic>r</italic> = −0.16, p = 0.0014), GABAa (mean <italic>r</italic> = −0.12, p = 0.0149), and NET (mean <italic>r</italic> = −0.13, p = 0.0157) (p<sub>FDR</sub> = 0.0157; <xref ref-type="fig" rid="fig2">Figure 2A</xref>). The directionality of these findings (i.e. a negative correlation) suggest bvFTD displayed stronger reductions in fALFF relative to HC in areas which are associated with a higher non-pathological density of respective receptors and transporters. When controlling for total GMV, the co-localization findings remained significant except for the co-localization with GABAa. The AUC resulting from the ROC curves between Spearman correlation coefficients of patients and controls revealed a good discrimination for 5-HT1b (AUC = 0.74) and 5-HT2a (AUC = 0.71) and a fair discrimination for GABAa (AUC = 0.68) and NET (AUC = 0.67) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Results of spatial correlation analyses with in vivo and mRNA data.</title><p>Correlation of fractional amplitude of low-frequency fluctuation (fALFF) (<bold>A</bold>) and gray matter volume (GMV) (<bold>B</bold>) with spatial distribution of neurotransmitter systems incl. 95% confidence intervals. Correlations of Verbal Fluency (<italic>N</italic> = 49) (<bold>C</bold>) and Mini Mental State Exam (<italic>N</italic> = 50) (<bold>D</bold>) with fALFF–neurotransmitter strength of association incl. bootstrapped 95% confidence intervals. Correlations of fALFF with mRNA gene expression maps (<italic>N</italic> = 52) (<bold>E</bold>). Statistically significant correlations in (<bold>A</bold>), (<bold>B</bold>), and (<bold>E</bold>) are marked in red and means are represented by white circles. Black circles in (<bold>A</bold>), (<bold>B</bold>), and (<bold>E</bold>) represent individual Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients for each patient (<italic>N</italic> = 52) relative to controls with each neurotransmitter map. Colored circles in (<bold>C</bold>) and (<bold>D</bold>) represent individual Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients between fALFF–neurotransmitter correlations and each neuropsychological scale. The statistical significance of all correlation coefficients was evaluated at p &lt; 0.05 including FDR correction for (<bold>A</bold>), (<bold>B</bold>), and (<bold>E</bold>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients shown in <xref ref-type="fig" rid="fig2">Figure 2A–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86085-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Results of spatial correlation of fractional amplitude of low-frequency fluctuation (fALFF) with mRNA gene expression maps of all γ-aminobutyric acid type A (GABAa) subunits.</title><p>Spearman correlation coefficients of mRNA gene expression maps with fALFF for all GABAa subunits (<italic>N</italic> = 52) (<bold>A</bold>) and their corresponding correlation matrix (<bold>B</bold>).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients of fractional amplitude of low-frequency fluctuation (fALFF) with mRNA gene expression of all γ-aminobutyric acid type A (GABAa) subunits shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86085-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig2-figsupp1-v1.tif"/></fig></fig-group><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Results for fractional amplitude of low-frequency fluctuation (fALFF)–neurotransmitter receiver operating characteristic (ROC) curve, correlations of fALFF–neurotransmitter and gray matter volume (GMV)–neurotransmitter correlations, correlations of neurotransmitter and mRNA gene expression maps, and autocorrelations of mRNA gene expression maps.</title><p>ROC curves for healthy controls (HC) vs. behavioral variant frontotemporal dementia (bvFTD) patients are displayed for significant fALFF–neurotransmitter correlations (<italic>N</italic><sub>bvFTD</sub> = 52, <italic>N</italic><sub>HC</sub> = 22) (<bold>A</bold>). Spearman correlation coefficients of fALFF–neurotransmitter and GMV–neurotransmitter correlations are displayed for each patient and each significant neurotransmitter (<italic>N</italic> = 52) (<bold>B</bold>). Spearman correlation coefficients of neurotransmitter and mRNA gene expression maps (<bold>C</bold>) and autocorrelations of mRNA gene expression maps averaged across mRNA donors (<italic>N</italic> = 6) (<bold>D</bold>) are displayed for significant fALFF–neurotransmitter associations incl. 95% confidence intervals.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Sensitivity and 1 − specificity shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, fractional amplitude of low-frequency fluctuation (fALFF)–neurotransmitter and gray matter volume (GMV)–neurotransmitter Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>, and Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients of neurotransmitter and mRNA gene expression maps shown in <xref ref-type="fig" rid="fig3">Figure 3C ,D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86085-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Results for correlations of neurotransmitter and mRNA gene expression mapsof all γ-aminobutyric acid type A (GABAa) subunits.</title><p>Spearman correlation coefficients of mRNA gene expression maps with the GABAa neurotransmitter map (<italic>N</italic> = 6) (<bold>A</bold>) and their mRNA autocorrelations (<italic>N</italic> = 6) (<bold>B</bold>). The genes encoding the 19 GABAa subunits include GABRA1–6, GABRB1–3, GABRG1–3, GABRR1–3, GABRD, GABRE, GABRP, and GABRQ. Means are represented by white circles.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Fisher’s <italic>z</italic>-transformed Spearman correlation coefficients of neurotransmitter and mRNA gene expression maps for all γ-aminobutyric acid type A (GABAa) subunits shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-86085-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86085-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Next, we tested if similar co-localization patterns are observed with GMV. GMV alterations in bvFTD were not significantly associated with any of the neurotransmitter systems (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). fALFF–neurotransmitter and GMV–neurotransmitter correlations displayed a positive yet weak association with structural alterations explaining only 10% of variance in the fALFF alterations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). All correlations and their corresponding permutation-based p-values incl. the analysis utilizing fALFF images additionally corrected for total GMV are provided in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>. To exclude a potential bias caused by the collection of imaging data at different sites, we performed a Kruskal–Wallis test to examine differences on the Fisher’s <italic>z</italic>-transformed correlations coefficients across sites. No significant differences (<italic>X</italic>² = 6.34, p = 0.50, df = 7) were found among the sites.</p></sec><sec id="s3-3"><title>Relationship to clinical symptoms</title><p>Furthermore, we tested if the significant fALFF–neurotransmitter correlation coefficients are also associated with symptoms or test results of bvFTD. After FDR correction (p = 0.0085), the strength of fALFF co-localization with NET distribution was significantly associated with VF (mean <italic>r</italic> = 0.37, p = 0.0086; <italic>N</italic> = 49; <xref ref-type="fig" rid="fig2">Figure 2C</xref>) and MMSE (mean <italic>r</italic> = 0.40, p = 0.0039; <italic>N</italic> = 50; <xref ref-type="fig" rid="fig2">Figure 2D</xref>). The positive correlation coefficients suggest that more negative correlations between fALFF and neurotransmitter maps were associated with lower test performance, that is the higher/more fALFF reductions in areas with high neurotransmitter density, the lower the test performance. Associations with other neuropsychological tests were not significant (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). We also tested if Eigenvariates extracted from the largest cluster of the HC &gt; bvFTD contrast correlated with the specific symptoms of bvFTD (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). None of the correlations remained significant after correction for multiple comparisons.</p></sec><sec id="s3-4"><title>Association with gene expression profile maps</title><p>Next, we evaluated if co-localization of fALFF is also observed with mRNA gene expression underlying the significantly associated neurotransmitter systems. For genes encoding the 19 GABAa subunits, we first evaluated the variability between the subunits regarding their fALFF–mRNA correlations, their correlation with GABAa density and their mRNA autocorrelations (see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). As the variability between the genes was high, we limited the analyses to genes encoding the three main subunits (GABRA1, GABRB1, and GABRG1).</p><p>Correlations of fALFF alterations with mRNA gene expression profile maps in bvFTD relative to HC differed significantly from zero for <italic>HTR1B</italic> (encoding the 5-HT1b receptor; mean <italic>r</italic> = −0.02, p = 0.0144), <italic>HTR2A</italic> (encoding the 5-HT2a receptor; mean <italic>r</italic> = −0.04, p &lt; 0.001), <italic>GABRB1</italic> (encoding subunit of the GABAa receptor; mean <italic>r</italic> = −0.08, p &lt; 0.001) and <italic>SLC6A2</italic> (encoding NET; mean <italic>r</italic> = 0.06, p &lt; 0.001), but not for GABRA1 (encoding subunit of the GABAa receptor; mean <italic>r</italic> = 0.02, p = 0.1414) and GABRG1 (encoding subunit of the GABAa receptor; mean <italic>r</italic> = −0.03, p = 0.0730) (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Thereby, correlations were negative for <italic>HTR1B</italic>, <italic>HTR2A</italic>, and <italic>GABRB1</italic>, that is fALFF was reduced in areas with higher expression of respective genes, and positive for <italic>SLC6A2</italic>.</p><p>Furthermore, we tested if there was an association between the neurotransmitter maps included in the JuSpace toolbox and the mRNA gene expression profile maps provided in the MENGA toolbox that were both derived from independent healthy volunteer populations. The correlations between spatial distributions of 5-HT1b, 5-HT2a, GABAa, and NET, and corresponding mRNA gene expression profile maps were positive (5-HT1b/<italic>HTR1B</italic>: mean <italic>r</italic> = 0.12; 5-HT2a/<italic>HTR2A</italic>: mean <italic>r</italic> = 0.20; GABAa/<italic>GABRA1</italic>: mean <italic>r</italic> = 0.14; GABAa/<italic>GABRB1</italic>: mean <italic>r</italic> = 0.14; NET/<italic>SLC6A2</italic>: mean <italic>r</italic> = 0.02) with exception of the GABRG1 gene (GABAa/<italic>GABRG1</italic>: mean <italic>r</italic> = −0.13) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Positive correlation coefficients suggest that higher neurotransmitter density was associated with higher expression of those neurotransmitters.</p><p>Lastly, to evaluate the robustness of the mRNA analyses (i.e. gene differential stability), genomic autocorrelations were calculated. The genomic autocorrelation was high for <italic>GABRB1</italic> (mean <italic>r</italic> = 0.92) and <italic>GABRG1</italic> (mean <italic>r</italic> = 0.64), small for <italic>HTR1B</italic> (mean <italic>r</italic> = 0.23), <italic>SLC6A2</italic> (mean <italic>r</italic> = 0.22), and <italic>GABRA1</italic> (mean <italic>r</italic> = 0.21), and very small for <italic>HTR2A</italic> (mean <italic>r</italic> = 0.05) (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>In the current study, we examined if there is a selective vulnerability of specific neurotransmitter systems in bvFTD to gain novel insight into the disease mechanisms underlying functional and structural alterations. More specifically, we evaluated if fALFF alterations in bvFTD co-localize with specific neurotransmitter systems. We found a significant spatial co-localization between fALFF alterations in patients and the in vivo derived distribution of specific receptors and transporters covering serotonergic, norepinephrinergic, and GABAergic neurotransmission. These fALFF–neurotransmitter associations were also observed at the mRNA expression level and their strength correlated with specific clinical symptoms. All of the observed co-localizations with in vivo derived neurotransmitter estimates were negative with lower fALFF values in bvFTD being associated with a higher density of the respective receptors and transporters in health. The directionality of these findings supports the notion of higher vulnerability of respective networks to disease-related alterations. These findings are also largely in line with previous research concerning FTD showing alterations in all of the respective neurotransmitter systems (<xref ref-type="bibr" rid="bib29">Huey et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Murley and Rowe, 2018</xref>).</p><p>The in vivo co-localization findings might also support the notion that propagation of proteins involved in bvFTD may align with specific neurotransmitter systems (<xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>). With regard to other brain disorders, linking functional connectivity with receptor density and expression, recent studies found an association between functional connectivity and receptor availability in schizophrenia, and an association between structural–functional decoupling and receptor gene expression in Parkinson’s disease (<xref ref-type="bibr" rid="bib66">Zarkali et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Horga et al., 2016</xref>). A potential mechanism for the selective vulnerability of specific neurotransmitter systems is the propagation of proteins along functionally connected networks that has been previously demonstrated for various neurodegenerative diseases (<xref ref-type="bibr" rid="bib67">Zhou et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Seeley et al., 2009</xref>). For example, in Alzheimer’s disease and normal aging, tau levels closely correlated with functional connectivity (<xref ref-type="bibr" rid="bib15">Franzmeier et al., 2019</xref>). We found moderate to large AUC when using the strength of the identified co-localizations for differentiation between patients and HC suggesting that these findings may represent a measure of the affectedness of respective neurotransmitter systems. In bvFTD, neurodegeneration is thought to progress through the salience network involved in socioemotional tasks, which comprises the anterior cingulate and frontoinsular cortex, as well as the amygdala and the striatum (<xref ref-type="bibr" rid="bib3">Bang et al., 2015</xref>; <xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>). The three neurotransmitter systems found to be deficient in our sample are relevant for the functioning of these structures (anterior cingulate cortex: e.g. serotonin and norepinephrine, <xref ref-type="bibr" rid="bib61">Tian et al., 2017</xref>; <xref ref-type="bibr" rid="bib34">Koga et al., 2020</xref>; amygdala: e.g. GABA and serotonin, <xref ref-type="bibr" rid="bib5">Castro-Sierra et al., 2005</xref>; striatum: e.g. GABA, <xref ref-type="bibr" rid="bib58">Semba et al., 1987</xref>). Although spread of misfolded proteins through the salience network provides a potential disease mechanism, further research of the exact mechanisms involved is needed.</p><p>For GMV, we did not find any significant co-localization with specific neurotransmitter systems. As the correlations with GMV showed a distinct pattern to fALFF and the variance explained by GMV in the observed fALFF–neurotransmitter associations was small, the observed associations with fALFF seem to be driven indeed by functional alterations and not by the underlying atrophy of respective regions. As propagation of misfolded proteins leads to a gradual dysfunction and eventually cell death (<xref ref-type="bibr" rid="bib26">Hock and Polymenidou, 2016</xref>), some regions displaying high density of a specific neurotransmitter might suffer dysfunction (i.e. functional alterations), whereas others might already be exposed to cell death (i.e. structural alterations/atrophy). An interesting future direction might compose integration of structural connectivity as measured by diffusion tensor imaging. A study by <xref ref-type="bibr" rid="bib10">Dopper et al., 2014</xref> showed reduced fractional anisotropy in healthy individuals carrying mutations compared to non-carriers (<xref ref-type="bibr" rid="bib10">Dopper et al., 2014</xref>). Given that there were structural connectivity differences even before disease onset, it would be of interest to re-examine structural connectivity differences between HC and patients (i.e. after disease onset). Repeating the neurotransmitter analyses might facilitate understanding of the underlying disease mechanism.</p><p>The strength of co-localization of fALFF with NET was correlated with VF and MMSE, both being impaired in patients with bvFTD (<xref ref-type="bibr" rid="bib54">Schroeter et al., 2012</xref>; <xref ref-type="bibr" rid="bib8">Diehl and Kurz, 2002</xref>; <xref ref-type="bibr" rid="bib56">Schroeter et al., 2018</xref>). Thereby, a stronger negative co-localization (i.e. lower fALFF in patients in high-density regions in health) was moderately associated with decreased test performance. Similarly, a correlation between MMSE and NE plasma concentration has been previously reported in Alzheimer’s disease (<xref ref-type="bibr" rid="bib43">Pillet et al., 2020</xref>). Combined, these findings point to a potentially more general role of norepinephrinergic neurotransmission in cognitive decline observed across different dementia syndromes. This interpretation is in line with the recently proposed role of the locus coeruleus, the source of norepinephrine in the brain, in regulating processes of learning, memory, and attention (<xref ref-type="bibr" rid="bib62">Tsukahara and Engle, 2021</xref>). In contrast to the study by <xref ref-type="bibr" rid="bib39">Murley et al., 2020</xref> who reported an association of GABA concentrations in the inferior frontal gyrus in FTD with disinhibition, we did not find this association. Beside the use of different methodology, a potential explanation may constitute the use of different inhibition measures. Whereas we measured disinhibition using the FrSBe, <xref ref-type="bibr" rid="bib39">Murley et al., 2020</xref> used a stop-signal task.</p><p>Although, except for α1 and γ1 GABAa subunits, all of the co-localizations with fALFF identified with in vivo estimates were also significant at the respective mRNA gene expression level, we found correlation coefficients of both directionalities. Interestingly, whereas these correlations were solely negative for the in vivo derived maps, the correlations with gene expression profile maps were positive for NET, and negative for 5-HT1b, 5-HT2a, and β1 GABAa subunit. Thus, for NET, we observed higher fALFF values in bvFTD patients in areas with high mRNA gene expression in health, whereas for 5-HT1b, 5-HT2a, and β1 GABAa subunit we observed lower fALFF values in bvFTD patients in areas with high mRNA gene expression in health. One explanation for these seemingly contradictory findings is that mRNA gene expression seems to vary strongly between individuals. In our mRNA gene expression profile maps, the autocorrelation between mRNA donors was low for 5-HT1b, 5-HT2a, and α1 GABAa subunit, and NET, limiting the confidence in some of these findings. Additionally, the association of mRNA expression with protein products may also vary greatly between genes, being not associated at all or even negatively associated for some, and strongly correlated for others (<xref ref-type="bibr" rid="bib35">Koussounadis et al., 2015</xref>; <xref ref-type="bibr" rid="bib37">Moritz et al., 2019</xref>). Similarly, a previous study found the correspondence between receptor density and mRNA expression to be low (<xref ref-type="bibr" rid="bib21">Hansen et al., 2022</xref>). Potential reasons for the lack of or even negative correlations may be a decoupling in time as well as that other levels of regulation overrode the transcriptional level (<xref ref-type="bibr" rid="bib35">Koussounadis et al., 2015</xref>). We observed a similar phenomenon in our data with the correlation of neurotransmitter density maps with their underlying mRNA gene expression being weak for all neurotransmitters except β1 and γ1 GABAa subunits.</p><p>Our findings support the notion of fALFF as useful marker for assessing bvFTD-related decline in brain function. In line with previous literature in bvFTD, we observe fALFF reductions mainly in frontal and temporal lobes, but also in the parietal lobe (<xref ref-type="bibr" rid="bib44">Premi et al., 2014</xref>; <xref ref-type="bibr" rid="bib4">Borroni et al., 2018</xref>). These findings support the notion of fALFF being a useful marker of metabolic impairment (<xref ref-type="bibr" rid="bib3">Bang et al., 2015</xref>; <xref ref-type="bibr" rid="bib9">Diehl-Schmid et al., 2007</xref>). Moreover, we found a clear association of fALFF with several neurotransmitter systems pointing to a selective neurotransmitter vulnerability in bvFTD, as suggested in previous research (<xref ref-type="bibr" rid="bib29">Huey et al., 2006</xref>; <xref ref-type="bibr" rid="bib38">Murley and Rowe, 2018</xref>). In particular, the co-localization of fALFF with NET was associated with VF and MMSE, suggesting the sensitivity of fALFF to reflect modality-specific cognitive decline.</p><p>The current study was limited by the unavailability of medication information. Therefore, we were not able to control for its potential confounding effects. However, as bvFTD medication is typically restricted to serotonin reuptake inhibitors its effects should be primarily associated with availability of 5-HTT and directionally negate the effects of the disease. Furthermore, as the included PET maps were derived from healthy subjects, the applied approach only tests for co-localization of imaging changes with the non-pathological distribution of the respective neurotransmitter systems. Similarly, the reliability of the co-localization analyses is partly limited by the number of healthy volunteers used to derive the respective neurotransmitter average maps. Finally, the current study was limited by the availability of neurotransmitter maps included in the JuSpace toolbox.</p><p>To summarize, we found fALFF reductions in bvFTD to co-localize with the in vivo and ex vivo derived distribution of serotonergic, GABAergic, and norepinephrinergic neurotransmitter systems, pointing to a crucial vulnerability of these neurotransmitters. The strength of these associations was linked to some of the neuropsychological deficits observed in this disease. We propose a combination of spread of pathology through neuronal connectivity and more specifically, through the salience network, as a disease mechanism. Thereby, these findings provide novel insight into the mechanisms underlying the spatial constraints observed in progressive functional and structural alterations in bvFTD. Our data-driven method might even be used to generate new hypotheses for pharmacological intervention in neuropsychiatric diseases beyond this disorder.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Life Molecular Imaging and Novartis/AAA. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf3"><p>has received consulting fees from, and currently act as a consultant for Aviado Bio, Prevail, Servier, Reata and Orphazyme. They have received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GenOrph. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf4"><p>has received consulting fees from Boehringer-Ingelheim, F. Hoffmann-La Roche, Biogen, Immungenetics, Roboscreen and Abbott. They currently act as a consultant for Boehringer-Ingelheim, F. Hoffmann-La Roche, Biogen and Immungenetics, and hold a Leadership or fiduciary role at CSF Society, AGNP and DGLN. The author has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, Janssen, MSD SHARP &amp; DOHME, Amgen, Roche Pharma, Actelion Pharmaceutical, Guangzhou Glorylen Medicial Technology Co. (China), Bejing Yibai Science and Technology Ltd. The author has been issued the following patents; EP2095128B1 and EP3105589A1. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf5"><p>has received a speaker fee from Jansen and Roche. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf6"><p>has received grants from BMBF - FTLD consortium, moodmarker, ALS association and EU - MIRIADE. The author has received consulting fees from, and currently acts as a consultant for, BIOGEN, Axon and Roche. The author has been issued a patent for Foundation state Baden-Wuerttemberg, Beta Syn as Biomarker for neurodegenerative diseases. The author holds an unpaid leadership or fiduciary role at the German Society for CSF diagnostics and neurochemistry and the Society for CSF diagnostics and neurochemistry, and as a speaker at the FTLD consortium. The author is co-inventor of a patent application (PCT/EP2020/072559) for using beta-synuclein measurement in blood.The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf7"><p>former employee of and current consultant for F.Hoffmann-La Roche</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Formal analysis, Investigation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Data curation, Funding acquisition</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Data curation, Funding acquisition, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Written informed consent was collected from each participant. The study was approved by the ethics committees of all universities involved in the German Consortium for Frontotemporal Lobar Degeneration (Ethics Committee University of Ulm approval number 20/10) and was in accordance with the latest version of the Declaration of Helsinki.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables including information about the subject distribution across centers, detailed information about the neurotransmitter maps, contrast peak voxel information for the t-contrasts, Spearman correlation coefficients and corresponding p-values from the fALFF- and GMV-neurotransmitter analyses and their relationship to clinical symptoms.</title></caption><media xlink:href="elife-86085-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86085-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The original data and their derivatives cannot be made publicly available as the study includes sensitive patient data and public data sharing was not covered in the informed consent. The original data supporting the findings of this study are available from the senior author (Matthias L. Schroeter) upon reasonable request. All derived statistical measures used here are available from the first author upon request. The software applied is publicly available at <ext-link ext-link-type="uri" xlink:href="https://github.com/juryxy/JuSpace">https://github.com/juryxy/JuSpace</ext-link> (JuSpace, <xref ref-type="bibr" rid="bib31">Juryxy, 2023</xref>) and <ext-link ext-link-type="uri" xlink:href="https://github.com/FAIR-CNS/MENGA">https://github.com/FAIR-CNS/MENGA</ext-link> (MENGA, <xref ref-type="bibr" rid="bib48">Rizzo, 2016</xref>). The code for the main analyses is publicly available at <ext-link ext-link-type="uri" xlink:href="https://github.com/liha-coding/Neurotransmitter-vulnerability-in-bvFTD">https://github.com/liha-coding/Neurotransmitter-vulnerability-in-bvFTD</ext-link> (copy archived at <xref ref-type="bibr" rid="bib20">Hahn, 2023</xref>). Processed data used for the creation of the figures are available as supplementary material.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This study has been supported by the German Consortium for Frontotemporal Lobar Degeneration, funded by the German Federal Ministry of Education and Research (BMBF; grant no. FKZ01GI1007A). MLS has been furthermore supported by the German Research Foundation (DFG; SCHR 774/5-1) and the eHealthSax Initiative of the Sächsische Aufbaubank (SAB). Accordingly, this study is co-financed with tax revenue based on the budget approved by the Saxon state parliament. JD has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 826421, 'TheVirtualBrain-Cloud'. This work was further supported by the JPND grant 'GENFI-prox' (by DLR/BMBF to MLS, joint with MO). We would like to acknowledge the Clinic for Cognitive Neurology in Leipzig, Annerose Engel, Anke Marschhauser, and Maryna Polyakova.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghourian</surname><given-names>M</given-names></name><name><surname>Legault-Denis</surname><given-names>C</given-names></name><name><surname>Soucy</surname><given-names>JP</given-names></name><name><surname>Rosa-Neto</surname><given-names>P</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Kostikov</surname><given-names>A</given-names></name><name><surname>Gravel</surname><given-names>P</given-names></name><name><surname>Bédard</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [<sup>18</sup>F]-FEOBV</article-title><source>Molecular Psychiatry</source><volume>22</volume><fpage>1531</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.183</pub-id><pub-id pub-id-type="pmid">28894304</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aiello</surname><given-names>M</given-names></name><name><surname>Salvatore</surname><given-names>E</given-names></name><name><surname>Cachia</surname><given-names>A</given-names></name><name><surname>Pappatà</surname><given-names>S</given-names></name><name><surname>Cavaliere</surname><given-names>C</given-names></name><name><surname>Prinster</surname><given-names>A</given-names></name><name><surname>Nicolai</surname><given-names>E</given-names></name><name><surname>Salvatore</surname><given-names>M</given-names></name><name><surname>Baron</surname><given-names>JC</given-names></name><name><surname>Quarantelli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Relationship between simultaneously acquired resting-state regional cerebral glucose metabolism and functional MRI: a PET/MR hybrid scanner study</article-title><source>NeuroImage</source><volume>113</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2015.03.017</pub-id><pub-id pub-id-type="pmid">25791784</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>J</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Frontotemporal dementia</article-title><source>Lancet</source><volume>386</volume><fpage>1672</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00461-4</pub-id><pub-id pub-id-type="pmid">26595641</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Benussi</surname><given-names>A</given-names></name><name><surname>Premi</surname><given-names>E</given-names></name><name><surname>Alberici</surname><given-names>A</given-names></name><name><surname>Marcello</surname><given-names>E</given-names></name><name><surname>Gardoni</surname><given-names>F</given-names></name><name><surname>Di Luca</surname><given-names>M</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biological, neuroimaging, and neurophysiological markers in frontotemporal dementia: three faces of the same coin</article-title><source>Journal of Alzheimer’s Disease</source><volume>62</volume><fpage>1113</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.3233/JAD-170584</pub-id><pub-id pub-id-type="pmid">29171998</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro-Sierra</surname><given-names>E</given-names></name><name><surname>de</surname><given-names>FCP</given-names></name><name><surname>Rivera</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Neurotransmitters of the limbic system Amygdala. I. Part one</article-title><source>Salud Mental</source><volume>28</volume><fpage>27</fpage><lpage>32</lpage></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>GS</given-names></name><name><surname>Farb</surname><given-names>NAS</given-names></name><name><surname>Tang-Wai</surname><given-names>DF</given-names></name><name><surname>Masellis</surname><given-names>M</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Pollock</surname><given-names>BG</given-names></name><name><surname>Chow</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Salience network resting-state activity: prediction of frontotemporal dementia progression</article-title><source>JAMA Neurology</source><volume>70</volume><fpage>1249</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2013.3258</pub-id><pub-id pub-id-type="pmid">23959214</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S</given-names></name><name><surname>Franklin</surname><given-names>CG</given-names></name><name><surname>O’Boyle</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Heyl</surname><given-names>BL</given-names></name><name><surname>Jerabek</surname><given-names>PA</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Fox</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hemodynamic and metabolic correspondence of resting-state voxel-based physiological metrics in healthy adults</article-title><source>NeuroImage</source><volume>250</volume><elocation-id>118923</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2022.118923</pub-id><pub-id pub-id-type="pmid">35066157</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl</surname><given-names>J</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Frontotemporal dementia: patient characteristics, cognition, and behaviour</article-title><source>International Journal of Geriatric Psychiatry</source><volume>17</volume><fpage>914</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1002/gps.709</pub-id><pub-id pub-id-type="pmid">12325050</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diehl-Schmid</surname><given-names>J</given-names></name><name><surname>Grimmer</surname><given-names>T</given-names></name><name><surname>Drzezga</surname><given-names>A</given-names></name><name><surname>Bornschein</surname><given-names>S</given-names></name><name><surname>Riemenschneider</surname><given-names>M</given-names></name><name><surname>Förstl</surname><given-names>H</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study</article-title><source>Neurobiology of Aging</source><volume>28</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2005.11.002</pub-id><pub-id pub-id-type="pmid">16448722</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dopper</surname><given-names>EGP</given-names></name><name><surname>Rombouts</surname><given-names>S</given-names></name><name><surname>Jiskoot</surname><given-names>LC</given-names></name><name><surname>den Heijer</surname><given-names>T</given-names></name><name><surname>de Graaf</surname><given-names>JRA</given-names></name><name><surname>de Koning</surname><given-names>I</given-names></name><name><surname>Hammerschlag</surname><given-names>AR</given-names></name><name><surname>Seelaar</surname><given-names>H</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Veer</surname><given-names>IM</given-names></name><name><surname>van Buchem</surname><given-names>MA</given-names></name><name><surname>Rizzu</surname><given-names>P</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia</article-title><source>Neurology</source><volume>83</volume><fpage>e19</fpage><lpage>e26</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000583</pub-id><pub-id pub-id-type="pmid">25002573</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dukart</surname><given-names>J</given-names></name><name><surname>Holiga</surname><given-names>Š</given-names></name><name><surname>Chatham</surname><given-names>C</given-names></name><name><surname>Hawkins</surname><given-names>P</given-names></name><name><surname>Forsyth</surname><given-names>A</given-names></name><name><surname>McMillan</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Merlo-Pich</surname><given-names>E</given-names></name><name><surname>Risterucci</surname><given-names>C</given-names></name><name><surname>Boak</surname><given-names>L</given-names></name><name><surname>Umbricht</surname><given-names>D</given-names></name><name><surname>Schobel</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>Zelaya</surname><given-names>FO</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Brown</surname><given-names>G</given-names></name><name><surname>Paulus</surname><given-names>M</given-names></name><name><surname>Honey</surname><given-names>GD</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S</given-names></name><name><surname>Hipp</surname><given-names>J</given-names></name><name><surname>Bertolino</surname><given-names>A</given-names></name><name><surname>Sambataro</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cerebral blood flow predicts differential neurotransmitter activity</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>4074</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-22444-0</pub-id><pub-id pub-id-type="pmid">29511260</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dukart</surname><given-names>J</given-names></name><name><surname>Holiga</surname><given-names>S</given-names></name><name><surname>Rullmann</surname><given-names>M</given-names></name><name><surname>Lanzenberger</surname><given-names>R</given-names></name><name><surname>Hawkins</surname><given-names>PCT</given-names></name><name><surname>Mehta</surname><given-names>MA</given-names></name><name><surname>Hesse</surname><given-names>S</given-names></name><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name><name><surname>Jech</surname><given-names>R</given-names></name><name><surname>Eickhoff</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps</article-title><source>Human Brain Mapping</source><volume>42</volume><fpage>555</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1002/hbm.25244</pub-id><pub-id pub-id-type="pmid">33079453</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eklund</surname><given-names>A</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name><name><surname>Knutsson</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates</article-title><source>PNAS</source><volume>113</volume><fpage>7900</fpage><lpage>7905</lpage><pub-id pub-id-type="doi">10.1073/pnas.1602413113</pub-id><pub-id pub-id-type="pmid">27357684</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Vloeberghs</surname><given-names>E</given-names></name><name><surname>Le Bastard</surname><given-names>N</given-names></name><name><surname>Van Buggenhout</surname><given-names>M</given-names></name><name><surname>Mariën</surname><given-names>P</given-names></name><name><surname>Somers</surname><given-names>N</given-names></name><name><surname>Nagels</surname><given-names>G</given-names></name><name><surname>Pickut</surname><given-names>BA</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia</article-title><source>Neurochemistry International</source><volume>52</volume><fpage>1052</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.10.018</pub-id><pub-id pub-id-type="pmid">18093695</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franzmeier</surname><given-names>N</given-names></name><name><surname>Rubinski</surname><given-names>A</given-names></name><name><surname>Neitzel</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Damm</surname><given-names>A</given-names></name><name><surname>Na</surname><given-names>DL</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Lyoo</surname><given-names>CH</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Finsterwalder</surname><given-names>S</given-names></name><name><surname>Duering</surname><given-names>M</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Ewers</surname><given-names>M</given-names></name><collab>Alzheimer’s disease neuroimaging initiative</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Functional connectivity associated with tau levels in ageing, Alzheimer’s, and small vessel disease</article-title><source>Brain</source><volume>142</volume><fpage>1093</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1093/brain/awz026</pub-id><pub-id pub-id-type="pmid">30770704</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García Gómez</surname><given-names>F</given-names></name><name><surname>Huertas</surname><given-names>I</given-names></name><name><surname>Lojo Ramírez</surname><given-names>J</given-names></name><name><surname>García Solís</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Elaboración de una plantilla de SPM para la normalización de imágenes de PET con 18F-DOPA</article-title><source>Imagen Diagnóstica</source><volume>9</volume><fpage>23</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.33588/imagendiagnostica.901.2</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Glenn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The Apathy Evaluation Scale. the Center for Outcome Measurement in Brain Injury</article-title><ext-link ext-link-type="uri" xlink:href="http://www.tbims.org/combi/aes">http://www.tbims.org/combi/aes</ext-link><date-in-citation iso-8601-date="2023-12-21">December 21, 2023</date-in-citation></element-citation></ref><ref id="bib18"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>J</given-names></name><name><surname>Malloy</surname><given-names>PH</given-names></name></person-group><year iso-8601-date="2001">2001</year><source>Frontal systems behavior scale (FrSBe): professional manual</source><publisher-name>Psychological Assessment Resources</publisher-name></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Frontotemporal dementia: from molecular mechanisms to therapy</article-title><source>Journal of Neurochemistry</source><volume>138 Suppl 1</volume><fpage>3</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/jnc.13619</pub-id><pub-id pub-id-type="pmid">27502123</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Neurotransmitter-vulnerability-in-bvFTD</data-title><version designator="swh:1:rev:6ac8351b5877dbfab984df2e76c4bb5c7b25c96d">swh:1:rev:6ac8351b5877dbfab984df2e76c4bb5c7b25c96d</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:4ad9cffb75a3ac40edbf568c2d414c45a84c102f;origin=https://github.com/liha-coding/Neurotransmitter-vulnerability-in-bvFTD;visit=swh:1:snp:5e807d79dccdad152520b4e652220ef418e7722a;anchor=swh:1:rev:6ac8351b5877dbfab984df2e76c4bb5c7b25c96d">https://archive.softwareheritage.org/swh:1:dir:4ad9cffb75a3ac40edbf568c2d414c45a84c102f;origin=https://github.com/liha-coding/Neurotransmitter-vulnerability-in-bvFTD;visit=swh:1:snp:5e807d79dccdad152520b4e652220ef418e7722a;anchor=swh:1:rev:6ac8351b5877dbfab984df2e76c4bb5c7b25c96d</ext-link></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JY</given-names></name><name><surname>Markello</surname><given-names>RD</given-names></name><name><surname>Tuominen</surname><given-names>L</given-names></name><name><surname>Nørgaard</surname><given-names>M</given-names></name><name><surname>Kuzmin</surname><given-names>E</given-names></name><name><surname>Palomero-Gallagher</surname><given-names>N</given-names></name><name><surname>Dagher</surname><given-names>A</given-names></name><name><surname>Misic</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain</article-title><source>NeuroImage</source><volume>264</volume><elocation-id>119671</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2022.119671</pub-id><pub-id pub-id-type="pmid">36209794</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>RJ</given-names></name><name><surname>Skelton-Robinson</surname><given-names>M</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The prevalence and causes of dementia in people under the age of 65 years</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>74</volume><fpage>1206</fpage><lpage>1209</lpage><pub-id pub-id-type="doi">10.1136/jnnp.74.9.1206</pub-id><pub-id pub-id-type="pmid">12933919</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></name><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>van de Lagemaat</surname><given-names>LN</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>ZL</given-names></name><name><surname>Abajian</surname><given-names>C</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Bertagnolli</surname><given-names>D</given-names></name><name><surname>Boe</surname><given-names>AF</given-names></name><name><surname>Cartagena</surname><given-names>PM</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Chapin</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>J</given-names></name><name><surname>Dalley</surname><given-names>RA</given-names></name><name><surname>David Daly</surname><given-names>B</given-names></name><name><surname>Dang</surname><given-names>C</given-names></name><name><surname>Datta</surname><given-names>S</given-names></name><name><surname>Dee</surname><given-names>N</given-names></name><name><surname>Dolbeare</surname><given-names>TA</given-names></name><name><surname>Faber</surname><given-names>V</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Fowler</surname><given-names>DR</given-names></name><name><surname>Goldy</surname><given-names>J</given-names></name><name><surname>Gregor</surname><given-names>BW</given-names></name><name><surname>Haradon</surname><given-names>Z</given-names></name><name><surname>Haynor</surname><given-names>DR</given-names></name><name><surname>Hohmann</surname><given-names>JG</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>RE</given-names></name><name><surname>Jeromin</surname><given-names>A</given-names></name><name><surname>Jochim</surname><given-names>JM</given-names></name><name><surname>Kinnunen</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Lazarz</surname><given-names>ET</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Lemon</surname><given-names>TA</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>JA</given-names></name><name><surname>Overly</surname><given-names>CC</given-names></name><name><surname>Parker</surname><given-names>PD</given-names></name><name><surname>Parry</surname><given-names>SE</given-names></name><name><surname>Reding</surname><given-names>M</given-names></name><name><surname>Royall</surname><given-names>JJ</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Sequeira</surname><given-names>PA</given-names></name><name><surname>Slaughterbeck</surname><given-names>CR</given-names></name><name><surname>Smith</surname><given-names>SC</given-names></name><name><surname>Sodt</surname><given-names>AJ</given-names></name><name><surname>Sunkin</surname><given-names>SM</given-names></name><name><surname>Swanson</surname><given-names>BE</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Wohnoutka</surname><given-names>P</given-names></name><name><surname>Zielke</surname><given-names>HR</given-names></name><name><surname>Geschwind</surname><given-names>DH</given-names></name><name><surname>Hof</surname><given-names>PR</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>SGN</given-names></name><name><surname>Jones</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An anatomically comprehensive atlas of the adult human brain transcriptome</article-title><source>Nature</source><volume>489</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1038/nature11405</pub-id><pub-id pub-id-type="pmid">22996553</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hesse</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>G-A</given-names></name><name><surname>Rullmann</surname><given-names>M</given-names></name><name><surname>Bresch</surname><given-names>A</given-names></name><name><surname>Luthardt</surname><given-names>J</given-names></name><name><surname>Hankir</surname><given-names>MK</given-names></name><name><surname>Zientek</surname><given-names>F</given-names></name><name><surname>Reißig</surname><given-names>G</given-names></name><name><surname>Patt</surname><given-names>M</given-names></name><name><surname>Arelin</surname><given-names>K</given-names></name><name><surname>Lobsien</surname><given-names>D</given-names></name><name><surname>Müller</surname><given-names>U</given-names></name><name><surname>Baldofski</surname><given-names>S</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name><name><surname>Blüher</surname><given-names>M</given-names></name><name><surname>Fasshauer</surname><given-names>M</given-names></name><name><surname>Fenske</surname><given-names>WK</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Hilbert</surname><given-names>A</given-names></name><name><surname>Ding</surname><given-names>Y-S</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Central noradrenaline transporter availability in highly obese, non-depressed individuals</article-title><source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>44</volume><fpage>1056</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1007/s00259-016-3590-3</pub-id><pub-id pub-id-type="pmid">28066877</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyburn</surname><given-names>L</given-names></name><name><surname>Moussa</surname><given-names>CE-H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TDP-43 overexpression impairs presynaptic integrity</article-title><source>Neural Regeneration Research</source><volume>11</volume><fpage>1910</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.195272</pub-id><pub-id pub-id-type="pmid">28197178</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hock</surname><given-names>EM</given-names></name><name><surname>Polymenidou</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prion-like propagation as a pathogenic principle in frontotemporal dementia</article-title><source>Journal of Neurochemistry</source><volume>138 Suppl 1</volume><fpage>163</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/jnc.13668</pub-id><pub-id pub-id-type="pmid">27502124</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holiga</surname><given-names>Š</given-names></name><name><surname>Sambataro</surname><given-names>F</given-names></name><name><surname>Luzy</surname><given-names>C</given-names></name><name><surname>Greig</surname><given-names>G</given-names></name><name><surname>Sarkar</surname><given-names>N</given-names></name><name><surname>Renken</surname><given-names>RJ</given-names></name><name><surname>Marsman</surname><given-names>J-BC</given-names></name><name><surname>Schobel</surname><given-names>SA</given-names></name><name><surname>Bertolino</surname><given-names>A</given-names></name><name><surname>Dukart</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Test-retest reliability of task-based and resting-state blood oxygen level dependence and cerebral blood flow measures</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0206583</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0206583</pub-id><pub-id pub-id-type="pmid">30408072</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horga</surname><given-names>G</given-names></name><name><surname>Cassidy</surname><given-names>CM</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Moore</surname><given-names>H</given-names></name><name><surname>Slifstein</surname><given-names>M</given-names></name><name><surname>Van Snellenberg</surname><given-names>JX</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia</article-title><source>JAMA Psychiatry</source><volume>73</volume><fpage>862</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.0178</pub-id><pub-id pub-id-type="pmid">27145361</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huey</surname><given-names>ED</given-names></name><name><surname>Putnam</surname><given-names>KT</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia</article-title><source>Neurology</source><volume>66</volume><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000191304.55196.4d</pub-id><pub-id pub-id-type="pmid">16401839</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huotari</surname><given-names>N</given-names></name><name><surname>Raitamaa</surname><given-names>L</given-names></name><name><surname>Helakari</surname><given-names>H</given-names></name><name><surname>Kananen</surname><given-names>J</given-names></name><name><surname>Raatikainen</surname><given-names>V</given-names></name><name><surname>Rasila</surname><given-names>A</given-names></name><name><surname>Tuovinen</surname><given-names>T</given-names></name><name><surname>Kantola</surname><given-names>J</given-names></name><name><surname>Borchardt</surname><given-names>V</given-names></name><name><surname>Kiviniemi</surname><given-names>VJ</given-names></name><name><surname>Korhonen</surname><given-names>VO</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sampling rate effects on resting state fMRI metrics</article-title><source>Frontiers in Neuroscience</source><volume>13</volume><elocation-id>279</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2019.00279</pub-id><pub-id pub-id-type="pmid">31001071</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="software"><person-group person-group-type="author"><collab>Juryxy</collab></person-group><year iso-8601-date="2023">2023</year><data-title>Juspace</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/juryxy/JuSpace">https://github.com/juryxy/JuSpace</ext-link></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaller</surname><given-names>S</given-names></name><name><surname>Rullmann</surname><given-names>M</given-names></name><name><surname>Patt</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>G-A</given-names></name><name><surname>Luthardt</surname><given-names>J</given-names></name><name><surname>Girbardt</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name><name><surname>Werner</surname><given-names>P</given-names></name><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Bresch</surname><given-names>A</given-names></name><name><surname>Fritz</surname><given-names>TH</given-names></name><name><surname>Hesse</surname><given-names>S</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Test-retest measurements of dopamine D<sub>1</sub>-type receptors using simultaneous PET/MRI imaging</article-title><source>European Journal of Nuclear Medicine and Molecular Imaging</source><volume>44</volume><fpage>1025</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1007/s00259-017-3645-0</pub-id><pub-id pub-id-type="pmid">28197685</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Caselli</surname><given-names>RJ</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Mendez</surname><given-names>MF</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Mercaldo</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Development of methodology for conducting clinical trials in frontotemporal lobar degeneration</article-title><source>Brain</source><volume>131</volume><fpage>2957</fpage><lpage>2968</lpage><pub-id pub-id-type="doi">10.1093/brain/awn234</pub-id><pub-id pub-id-type="pmid">18829698</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>XH</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Liu</surname><given-names>RH</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Zhan</surname><given-names>C</given-names></name><name><surname>Furue</surname><given-names>H</given-names></name><name><surname>Zhuo</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ascending noradrenergic excitation from the locus coeruleus to the anterior cingulate cortex</article-title><source>Molecular Brain</source><volume>13</volume><elocation-id>49</elocation-id><pub-id pub-id-type="doi">10.1186/s13041-020-00586-5</pub-id><pub-id pub-id-type="pmid">32216807</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koussounadis</surname><given-names>A</given-names></name><name><surname>Langdon</surname><given-names>SP</given-names></name><name><surname>Um</surname><given-names>IH</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>10775</elocation-id><pub-id pub-id-type="doi">10.1038/srep10775</pub-id><pub-id pub-id-type="pmid">26053859</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchitelli</surname><given-names>R</given-names></name><name><surname>Aiello</surname><given-names>M</given-names></name><name><surname>Cachia</surname><given-names>A</given-names></name><name><surname>Quarantelli</surname><given-names>M</given-names></name><name><surname>Cavaliere</surname><given-names>C</given-names></name><name><surname>Postiglione</surname><given-names>A</given-names></name><name><surname>Tedeschi</surname><given-names>G</given-names></name><name><surname>Montella</surname><given-names>P</given-names></name><name><surname>Milan</surname><given-names>G</given-names></name><name><surname>Salvatore</surname><given-names>M</given-names></name><name><surname>Salvatore</surname><given-names>E</given-names></name><name><surname>Baron</surname><given-names>JC</given-names></name><name><surname>Pappatà</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Simultaneous resting-state FDG-PET/fMRI in Alzheimer disease: relationship between glucose metabolism and intrinsic activity</article-title><source>NeuroImage</source><volume>176</volume><fpage>246</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2018.04.048</pub-id><pub-id pub-id-type="pmid">29709628</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moritz</surname><given-names>CP</given-names></name><name><surname>Mühlhaus</surname><given-names>T</given-names></name><name><surname>Tenzer</surname><given-names>S</given-names></name><name><surname>Schulenborg</surname><given-names>T</given-names></name><name><surname>Friauf</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Poor transcript-protein correlation in the brain: negatively correlating gene products reveal neuronal polarity as a potential cause</article-title><source>Journal of Neurochemistry</source><volume>149</volume><fpage>582</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1111/jnc.14664</pub-id><pub-id pub-id-type="pmid">30664243</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murley</surname><given-names>AG</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neurotransmitter deficits from frontotemporal lobar degeneration</article-title><source>Brain</source><volume>141</volume><fpage>1263</fpage><lpage>1285</lpage><pub-id pub-id-type="doi">10.1093/brain/awx327</pub-id><pub-id pub-id-type="pmid">29373632</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murley</surname><given-names>AG</given-names></name><name><surname>Rouse</surname><given-names>MA</given-names></name><name><surname>Jones</surname><given-names>PS</given-names></name><name><surname>Ye</surname><given-names>R</given-names></name><name><surname>Hezemans</surname><given-names>FH</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Frangou</surname><given-names>P</given-names></name><name><surname>Kourtzi</surname><given-names>Z</given-names></name><name><surname>Rua</surname><given-names>C</given-names></name><name><surname>Carpenter</surname><given-names>TA</given-names></name><name><surname>Rodgers</surname><given-names>CT</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition</article-title><source>Brain</source><volume>143</volume><fpage>3449</fpage><lpage>3462</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa305</pub-id><pub-id pub-id-type="pmid">33141154</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>JFM</given-names></name><name><surname>Rosso</surname><given-names>L</given-names></name><name><surname>Watson</surname><given-names>BJ</given-names></name><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Kalk</surname><given-names>NJ</given-names></name><name><surname>Clementi</surname><given-names>N</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name><name><surname>Lingford-Hughes</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Characterisation of the contribution of the GABA-benzodiazepine α1 receptor subtype to [(11)C]Ro15-4513 PET images</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>32</volume><fpage>731</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2011.177</pub-id><pub-id pub-id-type="pmid">22214903</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Ludolph</surname><given-names>AC</given-names></name><name><surname>Landwehrmeyer</surname><given-names>B</given-names></name><name><surname>Förstl</surname><given-names>H</given-names></name><name><surname>Diehl-Schmid</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Kretzschmar</surname><given-names>HA</given-names></name><name><surname>Schroeter</surname><given-names>M</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Danek</surname><given-names>A</given-names></name><collab>FTLD consortium</collab></person-group><year iso-8601-date="2011">2011</year><article-title>German consortium for frontotemporal lobar degeneration</article-title><source>Der Nervenarzt</source><volume>82</volume><fpage>1002</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1007/s00115-011-3261-3</pub-id><pub-id pub-id-type="pmid">21805118</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Penny</surname><given-names>WD</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Ashburner</surname><given-names>JT</given-names></name><name><surname>Kiebel</surname><given-names>SJ</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Statistical Parametric Mapping: The Analysis of Functional Brain Images</source><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillet</surname><given-names>LE</given-names></name><name><surname>Taccola</surname><given-names>C</given-names></name><name><surname>Cotoni</surname><given-names>J</given-names></name><name><surname>Thiriez</surname><given-names>H</given-names></name><name><surname>André</surname><given-names>K</given-names></name><name><surname>Verpillot</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Correlation between cognition and plasma noradrenaline level in Alzheimer’s disease: a potential new blood marker of disease evolution</article-title><source>Translational Psychiatry</source><volume>10</volume><elocation-id>213</elocation-id><pub-id pub-id-type="doi">10.1038/s41398-020-0841-7</pub-id><pub-id pub-id-type="pmid">32620743</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Premi</surname><given-names>E</given-names></name><name><surname>Cauda</surname><given-names>F</given-names></name><name><surname>Gasparotti</surname><given-names>R</given-names></name><name><surname>Diano</surname><given-names>M</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Multimodal FMRI resting-state functional connectivity in granulin mutations: the case of fronto-parietal dementia</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e106500</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0106500</pub-id><pub-id pub-id-type="pmid">25188321</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pressman</surname><given-names>PS</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Diagnosis and management of behavioral variant frontotemporal dementia</article-title><source>Biological Psychiatry</source><volume>75</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.11.006</pub-id><pub-id pub-id-type="pmid">24315411</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rascovsky</surname><given-names>K</given-names></name><name><surname>Hodges</surname><given-names>JR</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Mendez</surname><given-names>MF</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Neuhaus</surname><given-names>J</given-names></name><name><surname>van Swieten</surname><given-names>JC</given-names></name><name><surname>Seelaar</surname><given-names>H</given-names></name><name><surname>Dopper</surname><given-names>EGP</given-names></name><name><surname>Onyike</surname><given-names>CU</given-names></name><name><surname>Hillis</surname><given-names>AE</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Kertesz</surname><given-names>A</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Johnson</surname><given-names>JK</given-names></name><name><surname>Gorno-Tempini</surname><given-names>M-L</given-names></name><name><surname>Rosen</surname><given-names>H</given-names></name><name><surname>Prioleau-Latham</surname><given-names>CE</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Kipps</surname><given-names>CM</given-names></name><name><surname>Lillo</surname><given-names>P</given-names></name><name><surname>Piguet</surname><given-names>O</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Mesulam</surname><given-names>M</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Diehl-Schmid</surname><given-names>J</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Lebert</surname><given-names>F</given-names></name><name><surname>Pijnenburg</surname><given-names>Y</given-names></name><name><surname>Chow</surname><given-names>TW</given-names></name><name><surname>Manes</surname><given-names>F</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Cappa</surname><given-names>SF</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia</article-title><source>Brain</source><volume>134</volume><fpage>2456</fpage><lpage>2477</lpage><pub-id pub-id-type="doi">10.1093/brain/awr179</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>Gaia</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Heckemann</surname><given-names>RA</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Howes</surname><given-names>OD</given-names></name><name><surname>Hammers</surname><given-names>A</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>34</volume><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2014.21</pub-id><pub-id pub-id-type="pmid">24496175</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Multimodal environment for neuroimaging and Genomic analysis (MENGA)</data-title><version designator="3.1">3.1</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/FAIR-CNS/MENGA">https://github.com/FAIR-CNS/MENGA</ext-link></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Expert</surname><given-names>P</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MENGA: a new comprehensive tool for the integration of neuroimaging data and the allen human brain transcriptome atlas</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0148744</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148744</pub-id><pub-id pub-id-type="pmid">26882227</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandiego</surname><given-names>CM</given-names></name><name><surname>Gallezot</surname><given-names>JD</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Ropchan</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Morris</surname><given-names>ED</given-names></name><name><surname>Cosgrove</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Reference region modeling approaches for amphetamine challenge studies with [11C]FLB 457 and PET</article-title><source>Journal of Cerebral Blood Flow and Metabolism</source><volume>35</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2014.237</pub-id><pub-id pub-id-type="pmid">25564239</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savli</surname><given-names>M</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Mitterhauser</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>Y-S</given-names></name><name><surname>Hahn</surname><given-names>A</given-names></name><name><surname>Kroll</surname><given-names>T</given-names></name><name><surname>Neumeister</surname><given-names>A</given-names></name><name><surname>Haeusler</surname><given-names>D</given-names></name><name><surname>Ungersboeck</surname><given-names>J</given-names></name><name><surname>Henry</surname><given-names>S</given-names></name><name><surname>Isfahani</surname><given-names>SA</given-names></name><name><surname>Rattay</surname><given-names>F</given-names></name><name><surname>Wadsak</surname><given-names>W</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name><name><surname>Lanzenberger</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Normative database of the serotonergic system in healthy subjects using multi-tracer PET</article-title><source>NeuroImage</source><volume>63</volume><fpage>447</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.07.001</pub-id><pub-id pub-id-type="pmid">22789740</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Raczka</surname><given-names>K</given-names></name><name><surname>Neumann</surname><given-names>J</given-names></name><name><surname>von Cramon</surname><given-names>DY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Neural networks in frontotemporal dementia--a meta-analysis</article-title><source>Neurobiology of Aging</source><volume>29</volume><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.10.023</pub-id><pub-id pub-id-type="pmid">17140704</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Vogt</surname><given-names>B</given-names></name><name><surname>Frisch</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Seese</surname><given-names>A</given-names></name><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>K</given-names></name><name><surname>Villringer</surname><given-names>A</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dissociating behavioral disorders in early dementia—An FDG-PET study</article-title><source>Psychiatry Research</source><volume>194</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2011.06.009</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Vogt</surname><given-names>B</given-names></name><name><surname>Frisch</surname><given-names>S</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Barthel</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>K</given-names></name><name><surname>Villringer</surname><given-names>A</given-names></name><name><surname>Sabri</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Executive deficits are related to the inferior frontal junction in early dementia</article-title><source>Brain</source><volume>135</volume><fpage>201</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1093/brain/awr311</pub-id><pub-id pub-id-type="pmid">22184615</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Laird</surname><given-names>AR</given-names></name><name><surname>Chwiesko</surname><given-names>C</given-names></name><name><surname>Deuschl</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Bzdok</surname><given-names>D</given-names></name><name><surname>Eickhoff</surname><given-names>SB</given-names></name><name><surname>Neumann</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia</article-title><source>Cortex</source><volume>57</volume><fpage>22</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.cortex.2014.02.022</pub-id><pub-id pub-id-type="pmid">24763126</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Pawelke</surname><given-names>S</given-names></name><name><surname>Bisenius</surname><given-names>S</given-names></name><name><surname>Kynast</surname><given-names>J</given-names></name><name><surname>Schuemberg</surname><given-names>K</given-names></name><name><surname>Polyakova</surname><given-names>M</given-names></name><name><surname>Anderl-Straub</surname><given-names>S</given-names></name><name><surname>Danek</surname><given-names>A</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Jahn</surname><given-names>H</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Kornhuber</surname><given-names>J</given-names></name><name><surname>Lauer</surname><given-names>M</given-names></name><name><surname>Prudlo</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>A</given-names></name><name><surname>Uttner</surname><given-names>I</given-names></name><name><surname>Thöne-Otto</surname><given-names>A</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Diehl-Schmid</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A modified reading the mind in the eyes test predicts behavioral variant frontotemporal dementia better than executive function tests</article-title><source>Frontiers in Aging Neuroscience</source><volume>10</volume><elocation-id>11</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2018.00011</pub-id><pub-id pub-id-type="pmid">29441012</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Crawford</surname><given-names>RK</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Greicius</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Neurodegenerative diseases target large-scale human brain networks</article-title><source>Neuron</source><volume>62</volume><fpage>42</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2009.03.024</pub-id><pub-id pub-id-type="pmid">19376066</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semba</surname><given-names>K</given-names></name><name><surname>Fibiger</surname><given-names>HC</given-names></name><name><surname>Vincent</surname><given-names>SR</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Neurotransmitters in the mammalian striatum: neuronal circuits and heterogeneity</article-title><source>The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques</source><volume>14</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1017/s0317167100037781</pub-id><pub-id pub-id-type="pmid">2445456</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X-W</given-names></name><name><surname>Dong</surname><given-names>Z-Y</given-names></name><name><surname>Long</surname><given-names>X-Y</given-names></name><name><surname>Li</surname><given-names>S-F</given-names></name><name><surname>Zuo</surname><given-names>X-N</given-names></name><name><surname>Zhu</surname><given-names>C-Z</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>C-G</given-names></name><name><surname>Zang</surname><given-names>Y-F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>REST: a toolkit for resting-state functional magnetic resonance imaging data processing</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e25031</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025031</pub-id><pub-id pub-id-type="pmid">21949842</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svetoni</surname><given-names>F</given-names></name><name><surname>Frisone</surname><given-names>P</given-names></name><name><surname>Paronetto</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Role of FET proteins in neurodegenerative disorders</article-title><source>RNA Biology</source><volume>13</volume><fpage>1089</fpage><lpage>1102</lpage><pub-id pub-id-type="doi">10.1080/15476286.2016.1211225</pub-id><pub-id pub-id-type="pmid">27415968</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Yamanaka</surname><given-names>M</given-names></name><name><surname>Bernabucci</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>M-G</given-names></name><name><surname>Zhuo</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Characterization of serotonin-induced inhibition of excitatory synaptic transmission in the anterior cingulate cortex</article-title><source>Molecular Brain</source><volume>10</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s13041-017-0303-1</pub-id><pub-id pub-id-type="pmid">28606116</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>JS</given-names></name><name><surname>Engle</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Fluid intelligence and the locus coeruleus-norepinephrine system</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2110630118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2110630118</pub-id><pub-id pub-id-type="pmid">34764223</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration</article-title><source>Nature Reviews. Neuroscience</source><volume>17</volume><fpage>251</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.13</pub-id><pub-id pub-id-type="pmid">26988744</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitwell</surname><given-names>JL</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia</article-title><source>Journal of Molecular Neuroscience</source><volume>45</volume><fpage>372</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1007/s12031-011-9533-3</pub-id><pub-id pub-id-type="pmid">21556732</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolley</surname><given-names>JD</given-names></name><name><surname>Khan</surname><given-names>BK</given-names></name><name><surname>Murthy</surname><given-names>NK</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease</article-title><source>The Journal of Clinical Psychiatry</source><volume>72</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.4088/JCP.10m06382oli</pub-id><pub-id pub-id-type="pmid">21382304</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarkali</surname><given-names>A</given-names></name><name><surname>McColgan</surname><given-names>P</given-names></name><name><surname>Leyland</surname><given-names>LA</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Rees</surname><given-names>G</given-names></name><name><surname>Weil</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Organisational and neuromodulatory underpinnings of structural-functional connectivity decoupling in patients with Parkinson’s disease</article-title><source>Communications Biology</source><volume>4</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-01622-9</pub-id><pub-id pub-id-type="pmid">33469150</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Gennatas</surname><given-names>ED</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Predicting regional neurodegeneration from the healthy brain functional connectome</article-title><source>Neuron</source><volume>73</volume><fpage>1216</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.03.004</pub-id><pub-id pub-id-type="pmid">22445348</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>McInnes</surname><given-names>J</given-names></name><name><surname>Wierda</surname><given-names>K</given-names></name><name><surname>Holt</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>AG</given-names></name><name><surname>Jackson</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Swerts</surname><given-names>J</given-names></name><name><surname>Beyens</surname><given-names>J</given-names></name><name><surname>Miskiewicz</surname><given-names>K</given-names></name><name><surname>Vilain</surname><given-names>S</given-names></name><name><surname>Dewachter</surname><given-names>I</given-names></name><name><surname>Moechars</surname><given-names>D</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>De Wit</surname><given-names>J</given-names></name><name><surname>Verstreken</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tau association with synaptic vesicles causes presynaptic dysfunction</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15295</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15295</pub-id><pub-id pub-id-type="pmid">28492240</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86085.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.30.22278624" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.30.22278624"/></front-stub><body><p>This study presents important findings linking structural and functional changes in frontotemporal dementia to underlying neurotransmitter systems. The evidence to support the claims is solid, however, relationships are relatively modest. This study will appeal to clinicians and neuroscientists who are interested in the potential effects of certain neurotransmitter systems on clinical features of frontotemporal dementia.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86085.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ramanan</surname><given-names>Vijay</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02qp3tb03</institution-id><institution>Mayo Clinic</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.30.22278624">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.08.30.22278624v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Timothy Behrens as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Vijay Ramanam (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Introduction:</p><p>1. The authors use the raclopride tracer to measure D2 receptor availability in the cortex. According to Dagher and Palomero-Gallagher 2020, this tracer is not sufficiently sensitive to measure the low D2 availability in the cortex. I recommend the authors replace their raclopride tracer for fallypride/FLB-457, or provide justification for using raclopride.</p><p>Dagher, A., and Palomero-Gallagher, N. (2020). Mapping dopamine with positron emission tomography: A note of caution. Neuroimage, 207, 116203.</p><p>2. The text on &quot;prion-like propagation&quot; in the Introduction seems a bit strong, as this is hardly a settled view in the field (i.e., mechanisms of neurodegenerative disease include many hypotheses, this amongst them).</p><p>3. If I understand correctly, &quot;genomic autocorrelation&quot; is identical to gene differential stability (Hawrylycz et al. 2015). I recommend the authors use &quot;differential stability&quot; to keep language consistent in the literature and decrease confusion.</p><p>Hawrylycz, M., Miller, J. A., Menon, V., Feng, D., Dolbeare, T., Guillozet-Bongaarts, A. L., … and Lein, E. (2015). Canonical genetic signatures of the adult human brain. Nature neuroscience, 18(12), 1832-1844.</p><p>4. The neurotransmitters being considered are themselves a selective list of those involved in mental functioning pathways. Is this a limitation of the toolboxes/data sets utilized, or was this a pre-hoc specification? Would recommend this is discussed in the study limitations.</p><p>Methods and Results:</p><p>5. Please provide more details of the fMRI metric utilized and the evidence in support of it as a useful biomarker for bvFTD. For example, essentially only one paper describing fALFF as having a correlation with FDG hypometabolism is cited.</p><p>6. It would be useful to explain in greater detail how the maps of neurotransmitters are generated with the JuSpace toolbox. I suppose they are based on postmortem human brains. How many does it use, what are the demographics of these brains and how were the neurotransmitters determined?</p><p>7. Since the samples at each centre were small, the authors should assess the impact of different parameters in linear models, with fALFF as an output and the different parameters as predictors. Supplementary Table S2 should be moved to the main text so that the readers can see this information as they read the manuscript.</p><p>8. What was the rationale behind using 6 mm FWHM smoothing for gray matter volume analyses? This smoothing seems rather low, unless the authors were looking for results in small brain regions, which was not stated. A smoothing of 6 mm for an isotropic fMRI is appropriate but for T1-weighted images is different. Why didn't the authors used DARTEL for their VBM analyses? This greatly improves registration and eliminates potential mismatches between the images.</p><p>9. Typical fMRI is highly dependent on the underlying GM structure. Can the authors perform the same fMRI analyses comparing groups while controlling for total GM volume?</p><p>10. The major analyses test the fALFF-NT correlation coefficients against neuropsychological test performance. The fALFF-test and NT-test correlations should also be reported, as if either of these are stronger than the main findings it would suggest that there is not a specific fALFF-NT relationship that is really the driver here.</p><p>11. For the multiple comparison correction method, why did the authors choose permutation and did not use FDR or FWE provided by SPM? And why did they combine it with an uncorrected threshold? Similarly, the authors state &quot;corrections for autocorrelations were performed&quot; (line 216); could the authors expand on how this was done?</p><p>Discussion:</p><p>12. Would suggest greater comment in the Discussion on the neuropsychological test analyses. Only a few outcomes showed a nominal relationship with the fALFF-NT coefficients.</p><p>13. Sample sizes for D2 and GABAA tracers are quite small (&lt;10) which the authors should explicitly mention in the limitations or replicate with larger-N datasets.</p><p>14. The authors motivate studying fALFF in the Introduction but I felt this thread was lost in the Discussion. I recommend the authors expand on (in the Discussion) why fALFF is an appropriate and relevant measure to study in bvFTD, especially in light of their findings.</p><p>15. Given the hypothesis that prion-like proteins spread on the underlying structural network, an interesting future direction for this work would be to study structural connectivity instead of GMV. Since the authors mention this hypothesis in the Introduction (line 127), I felt some Discussion on this subject would be of interest, perhaps by expanding the paragraph that starts at line 377?</p><p>16. I recommend the authors give credit to previous studies that investigate the mRNA-protein density correlation. Some examples:</p><p>a. Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., … and Knudsen, G. M. (2017). A high-resolution in vivo atlas of the human brain's serotonin system. Journal of Neuroscience, 37(1), 120-128. (For findings regarding the serotonin system)</p><p>b. Nørgaard, M., Beliveau, V., Ganz, M., Svarer, C., Pinborg, L. H., Keller, S. H., … and Knudsen, G. M. (2021). A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors. NeuroImage, 232, 117878. (For findings regarding the GABAA system)</p><p>c. Hansen, J. Y., Markello, R. D., Tuominen, L., Nørgaard, M., Kuzmin, E., Palomero-Gallagher, N., … and Misic, B. (2022). Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain. Neuroimage, 264, 119671. (For showing generally low correspondence between receptor density and mRNA)</p><p>d. Rizzo, G., Veronese, M., Heckemann, R. A., Selvaraj, S., Howes, O. D., Hammers, A., … and Bertoldo, A. (2014). The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study. Journal of Cerebral Blood Flow and Metabolism, 34(5), 827. (To my knowledge, the first study to test the association between AHBA mRNA expression and imaging-derived receptor densities across the cortex.)</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>(1) The authors use the raclopride tracer to measure D2 receptor availability in the cortex. According to Dagher and Palomero-Gallagher 2020, this tracer is not sufficiently sensitive to measure the low D2 availability in the cortex. I recommend the authors replace their raclopride tracer for fallypride/FLB-45, or provide justification for using raclopride.</p><p>Dagher, A., and Palomero-Gallagher, N. (2020). Mapping dopamine with positron emission tomography: A note of caution. Neuroimage, 207, 116203.</p><p>(2) Sample sizes for D2 and GABAA tracers are quite small (&lt;10) which the authors should explicitly mention in the limitations or replicate with larger-N datasets.</p><p>(3) If I understand correctly, &quot;genomic autocorrelation&quot; is identical to gene differential stability (Hawrylycz et al. 2015). I recommend the authors use &quot;differential stability&quot; to keep language consistent in the literature and decrease confusion.</p><p>Hawrylycz, M., Miller, J. A., Menon, V., Feng, D., Dolbeare, T., Guillozet-Bongaarts, A. L., … and Lein, E. (2015). Canonical genetic signatures of the adult human brain. Nature neuroscience, 18(12), 1832-1844.</p><p>(4) The authors state &quot;corrections for autocorrelations were performed&quot; (line 216); could the authors expand on how this was done?</p><p>(5) I recommend the authors give credit to previous studies that investigate the mRNA-protein density correlation. Some examples:</p><p>a. Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., … and Knudsen, G. M. (2017). A high-resolution in vivo atlas of the human brain's serotonin system. Journal of Neuroscience, 37(1), 120-128. (For findings regarding the serotonin system)</p><p>b. Nørgaard, M., Beliveau, V., Ganz, M., Svarer, C., Pinborg, L. H., Keller, S. H., … and Knudsen, G. M. (2021). A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors. NeuroImage, 232, 117878. (For findings regarding the GABAA system)</p><p>c. Hansen, J. Y., Markello, R. D., Tuominen, L., Nørgaard, M., Kuzmin, E., Palomero-Gallagher, N., … and Misic, B. (2022). Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain. Neuroimage, 264, 119671. (For showing generally low correspondence between receptor density and mRNA)</p><p>d. Rizzo, G., Veronese, M., Heckemann, R. A., Selvaraj, S., Howes, O. D., Hammers, A., … and Bertoldo, A. (2014). The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study. Journal of Cerebral Blood Flow and Metabolism, 34(5), 827. (To my knowledge, the first study to test the association between AHBA mRNA expression and imaging-derived receptor densities across the cortex.)</p><p>(6) The authors motivate studying fALFF in the Introduction but I felt this thread was lost in the Discussion. I recommend the authors expand on (in the Discussion) why fALFF is an appropriate and relevant measure to study in bvFTD, especially in light of their findings.</p><p>(7) Given the hypothesis that prion-like proteins spread on the underlying structural network, an interesting future direction for this work would be to study structural connectivity instead of GMV. Since the authors mention this hypothesis in the Introduction (line 127), I felt some Discussion on this subject would be of interest, perhaps by expanding the paragraph that starts at line 377?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>One of the strengths of the study is the relatively large bvFTD cohort they used, which was recruited from different centres. A limitation associated with this is the fact that the scanning parameters were not exactly the same. For the T1-weighted images they seem relatively harmonised but for fMRI the voxel sizes were not isotropic and display some variability. Since the samples at each centre were small, the authors should assess the impact of different parameters in linear models, with fALFF as an output and the different parameters as predictors.</p><p>Supplementary Table S2 should be moved to the main text so that the readers can see this information as they read the manuscript.</p><p>What was the rationale behind using 6 mm FWHM smoothing for gray matter volume analyses? This smoothing seems rather low, unless the authors were looking for results in small brain regions, which was not stated.</p><p>A smoothing of 6 mm for an isotropic fMRI is appropriate but for T1-weighted images is different. Why didn't the authors use DARTEL for their VBM analyses? This greatly improves registration and eliminates potential mismatches between the images.</p><p>Typical fMRI is highly dependent on the underlying GM structure. Can the authors perform the same fMRI analyses comparing groups while controlling for total GM volume?</p><p>Which contrast is this: patients&gt;bvFTD? Line 192.</p><p>I don't understand the multiple comparison corrections method the authors used. Why did they choose permutation and did not use FDR or FWE provided by SPM? And why did they combine it with an uncorrected threshold?</p><p>The reference for the toolbox (JuSpace), which allows to correlate with neurotransmitter systems seems to be an abstract. Has this toolbox been published and used by other groups?</p><p>They should recognize the fact that the cognitive results did not survive correction for multiple comparisons as a limitation in the Discussion.</p><p>It would be useful to explain in greater detail how the maps of neurotransmitters are generated with the JuSpace toolbox. I suppose they are based on postmortem human brains. How many does it use, what are the demographics of these brains and how were the neurotransmitters determined?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>1. Would suggest a greater explanation of the fMRI metric utilized and the evidence in support of it as a useful biomarker for bvFTD. For example, essentially only one paper describing fALFF as having a correlation with FDG hypometabolism is cited.</p><p>2. The neurotransmitters being considered are themselves a selective list of those involved in mental functioning pathways. Is this a limitation of the toolboxes/data sets utilized, or was this a pre-hoc specification? Would recommend this is discussed in the study limitations.</p><p>3. The text on &quot;prion-like propagation&quot; in the Introduction seems a bit strong, as this is hardly a settled view in the field (i.e., mechanisms of neurodegenerative disease include many hypotheses, this amongst them).</p><p>4. The major analyses test the fALFF-NT correlation coefficients against neuropsychological test performance. The fALFF-test and NT-test correlations should also be reported, as if either of these are stronger than the main findings it would suggest that there is not a specific fALFF-NT relationship that is really the driver here.</p><p>5. Would suggest greater comment in the Discussion on the neuropsychological test analyses. Only a few outcomes showed a nominal relationship with the fALFF-NT coefficients.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86085.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Introduction:</p><p>1. The authors use the raclopride tracer to measure D2 receptor availability in the cortex. According to Dagher and Palomero-Gallagher 2020, this tracer is not sufficiently sensitive to measure the low D2 availability in the cortex. I recommend the authors replace their raclopride tracer for fallypride/FLB-457 or provide justification for using raclopride.</p><p>Dagher, A., and Palomero-Gallagher, N. (2020). Mapping dopamine with positron emission tomography: A note of caution. Neuroimage, 207, 116203.</p></disp-quote><p>We thank the reviewer for this suggestion and pointing out the weakness of the selected D2 tracer. We have now repeated the analysis using flb457 (please see Table S2 in supplement for the new tracer information). This changed the results so that the fALFF-NT correlation for D2 is no longer significant. We reported the new non-significant results in the main text and removed the respective findings including the follow-up analyses for fALFF-NT correlations with neuropsychological data and fALFF-mRNA correlations.</p><disp-quote content-type="editor-comment"><p>2. The text on &quot;prion-like propagation&quot; in the Introduction seems a bit strong, as this is hardly a settled view in the field (i.e., mechanisms of neurodegenerative disease include many hypotheses, this amongst them).</p></disp-quote><p>We thank the reviewer for this comment. We adjusted the text accordingly to include other theories as well:</p><p>“Several possible mechanisms are discussed in the literature for the spread of these proteins throughout the brain, from a selective neuronal vulnerability (i.e., specific neurons being inherently more susceptible to the underlying disease-related mechanisms) to prion-like propagation of the respective proteins.(18,19) The latter entails that misfolded proteins accumulate and induce a self-perpetuating process so that protein aggregates can spread and amplify, leading to gradual dysfunction and eventually death of neurons and glial cells.(19)”</p><p>Furthermore, we changed the expression prion-like propagation of the proteins to propagation of the proteins in the other parts of the paper, to be more cautious here.</p><disp-quote content-type="editor-comment"><p>3. If I understand correctly, &quot;genomic autocorrelation&quot; is identical to gene differential stability (Hawrylycz et al. 2015). I recommend the authors use &quot;differential stability&quot; to keep language consistent in the literature and decrease confusion.</p><p>Hawrylycz, M., Miller, J. A., Menon, V., Feng, D., Dolbeare, T., Guillozet-Bongaarts, A. L., … and Lein, E. (2015). Canonical genetic signatures of the adult human brain. Nature neuroscience, 18(12), 1832-1844.</p></disp-quote><p>We have now changed the term genomic autocorrelation to differential stability in the heading and the main text as well as cited the reference:</p><p>“Neurotransmitter-genomic correlations and gene differential stability</p><p>To evaluate the robustness of the mRNA maps between donors, gene differential stability was estimated by computing the Fisher’s Z transformed Spearman correlation coefficients between the genomic values of each of the six mRNA donors, which were then averaged.(49)”</p><disp-quote content-type="editor-comment"><p>4. The neurotransmitters being considered are themselves a selective list of those involved in mental functioning pathways. Is this a limitation of the toolboxes/data sets utilized, or was this a pre-hoc specification? Would recommend this is discussed in the study limitations.</p></disp-quote><p>We thank the reviewer for raising this issue. The neurotransmitters were not anyhow preselected but are due to the limited public availability of other PET maps. This is indeed a study limitation and we have now added the following sentence to the discussion:</p><p>“Finally, the current study was limited by the availability of neurotransmitter maps included in the JuSpace toolbox.”</p><disp-quote content-type="editor-comment"><p>Methods and Results:</p><p>5. Please provide more details of the fMRI metric utilized and the evidence in support of it as a useful biomarker for bvFTD. For example, essentially only one paper describing fALFF as having a correlation with FDG hypometabolism is cited.</p></disp-quote><p>We have now provided more details on fALFF. We added a short explanation on the calculation and added a further reference evaluating the correlation of fALFF with FDG PET. Unfortunately, there are indeed only very few publications we are aware of which collected and compared fALFF and FDG-PET measures in the same participants.</p><p>fALFF was calculated at each voxel as the root mean square of the blood oxygen level dependent signal amplitude in the analysis frequency band (here: 0.01 – 0.08 Hz) divided by the amplitude in the entire frequency band.(34) fALFF is closely linked to FDG-PET and other measures of local metabolic activity as has been shown in healthy participants but also for example in Alzheimer’s disease.(12,35)</p><p>12. Deng S, Franklin CG, O'Boyle M, Zhang W, Heyl BL, Jerabek PA, Lu H, Fox PT. Hemodynamic and metabolic correspondence of resting-state voxel-based physiological metrics in healthy adults. Neuroimage. 2022 Apr 15;250:118923.</p><p>35. Marchitelli R, Aiello M, Cachia A, Quarantelli M, Cavaliere C, Postiglione A, Tedeschi G, Montella P, Milan G, Salvatore M, Salvatore E, Baron JC, Pappatà S. Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity. Neuroimage. 2018 Aug 1;176:246-258. doi: 10.1016/j.neuroimage.2018.04.048. Epub 2018 Apr 27. PMID: 29709628.</p><disp-quote content-type="editor-comment"><p>6. It would be useful to explain in greater detail how the maps of neurotransmitters are generated with the JuSpace toolbox. I suppose they are based on postmortem human brains. How many does it use, what are the demographics of these brains and how were the neurotransmitters determined?</p></disp-quote><p>We thank the reviewer for this comment. The neurotransmitter maps are publicly available PET maps averaged across healthy volunteers hat were acquired in vivo (the details of these maps are provided in Table S3 and also in the original JuSpace publication). To make this more clear, we have now added the following explanations to the Methods section explaining ‘Spatial correlation with neurotransmitter density maps’:</p><p>“The JuSpace toolbox allows for cross-modal spatial correlations of different neuroimaging modalities with nuclear imaging derived information about the relative density distribution of various neurotransmitter systems. All neurotransmitter maps were derived as averages from an independent healthy volunteer population and processed as described in the JuSpace publication including rescaling and normalization into the Montreal Neurological Institute space.”</p><p>Detailed information about the publicly available neurotransmitter maps is provided in Table S3.</p><disp-quote content-type="editor-comment"><p>7. Since the samples at each centre were small, the authors should assess the impact of different parameters in linear models, with fALFF as an output and the different parameters as predictors. Supplementary Table S2 should be moved to the main text so that the readers can see this information as they read the manuscript.</p></disp-quote><p>We thank the reviewer for this suggestion. We would like to point out that we controlled all analyses for potential site effects to acknowledge the slightly differing acquisition parameters (e.g., by using dummy-coded site variables and regressing out their effect). Furthermore, the literature shows that acquisition parameters such as TR have little to no effect on conventional rsfMRI functional metrics such as fALFF, e.g.:</p><p>Huotari N, Raitamaa L, Helakari H, Kananen J, Raatikainen V, Rasila A, Tuovinen T, Kantola J, Borchardt V, Kiviniemi VJ, Korhonen VO. Sampling rate effects on resting state fMRI metrics. Frontiers in Neuroscience. 2019 Apr 2;13:279.</p><p>As suggested by the reviewer, we have moved Table S2 to the main text as Table 2.</p><disp-quote content-type="editor-comment"><p>8. What was the rationale behind using 6 mm FWHM smoothing for gray matter volume analyses? This smoothing seems rather low, unless the authors were looking for results in small brain regions, which was not stated. A smoothing of 6 mm for an isotropic fMRI is appropriate but for T1-weighted images is different. Why didn't the authors used DARTEL for their VBM analyses? This greatly improves registration and eliminates potential mismatches between the images.</p></disp-quote><p>We thank the reviewer for this comment. As our motivation for analyzing the structural data was to ensure that the observed functional effects are not driven by the underlying structural changes, we aimed to make the pre-processing as similar as possible between the structural and the resting state data being the main scope of our study. This was also our main reason for using 6mm FWHM for gray matter volume analyses to ensure that a similar smoothing as compared to the derived fALFF maps. For the same reason, we did not use DARTEL as we wanted to keep the normalization parameters identical between both modalities. Moreover, previous research using simulated atrophy showed that the optimal width of smoothing kernel depends on the group size for VBM analyses (Shen and Sterr, 2013). In this publication, for a group size of 50, 6 mm FWHM was recommended as the optimal width of smoothing kernel matching our choice.</p><p>Shen S, Sterr A. Is DARTEL‐based voxel‐based morphometry affected by width of smoothing kernel and group size? A study using simulated atrophy. Journal of Magnetic Resonance Imaging. 2013 Jun;37(6):1468-75.</p><disp-quote content-type="editor-comment"><p>9. Typical fMRI is highly dependent on the underlying GM structure. Can the authors perform the same fMRI analyses comparing groups while controlling for total GM volume?ta</p></disp-quote><p>We thank the reviewer for this comment. First, we would like to point out that for this very reason (to make sure that the observed functional effects are not driven by underlying structure), we have initially computed the SPM and JuSpace analysis using GMV as a control analysis to fALFF. In this analysis, GMV and fALFF showed very different results regarding SPM contrasts as well as neurotransmitter co-localization, demonstrating that the observed functional results are clearly distinct from underlying structural changes. Additionally, we have now repeated the SPM contrast and JuSpace analyses controlling for total GMV.</p><p>All effects remained significant after controlling for total GMV except for the co-localization with GABAA. We added the results of the SPM contrast analysis as additional row to Table S3 and the results of the JuSpace analysis as additional column (‘fALFF (corrected for GMV)’) to Table S4 in the supplement. Additionally, we briefly describe this analysis in the main text.</p><p>To further test if and how the observed fALFF co-localization patterns are explained by the underlying global atrophy, we repeated the co-localization analysis (p&lt;.05) for the significant fALFF-neurotransmitter associations after controlling for total GMV.</p><p>When controlling for total GMV, the co-localization findings remained significant except for the co-localization with GABAA.</p><p>Cluster size, peak-level MNI coordinates and corresponding anatomical regions incl. the additional fALFF analysis with correction for total GMV are reported in Table S4.</p><p>All correlations and their corresponding permutation-based p-values incl. the analysis utilizing fALFF images additionally corrected for total GMV are provided in Table S5.</p><disp-quote content-type="editor-comment"><p>10. The major analyses test the fALFF-NT correlation coefficients against neuropsychological test performance. The fALFF-test and NT-test correlations should also be reported, as if either of these are stronger than the main findings it would suggest that there is not a specific fALFF-NT relationship that is really the driver here.</p></disp-quote><p>We thank the reviewer for this suggestion. We have now examined the fALFF-test correlations using Spearman correlations between the neuropsychological tests and the Eigenvariates of the largest cluster of the controls&gt;patients SPM contrast (please see Table S6 in the supplement). The correlations were not significant after FDR correction. Only the Clinical Dementia Rating for Frontotemporal Lobar Degeneration was significantly correlated with fALFF using an uncorrected threshold of p = 0.05. The weaker nature of these correlations as well as association with different scales both point to the specific nature of the fALFF-NT correlations with neuropsychological tests. Unfortunately, it is not possible to examine the NT-test correlations since the neurotransmitter average maps were collected from different healthy volunteer populations as addressed in point 6 raised by the reviewer. We have now added a description of this analysis and the results to the main text of the manuscript.</p><p>Methods:</p><p>“In addition, to test for the specificity of these associations we examined the direct associations between fALFF and the neuropsychological tests by computing Spearman correlations with the Eigenvariates extracted from the largest cluster of the HC&gt;bvFTD SPM contrast.”</p><p>Results:</p><p>“We also tested if Eigenvariates extracted from the largest cluster of the HC&gt;bvFTD contrast correlated with the specific symptoms of bvFTD (Table S6). None of the correlations remained significant after correction for multiple comparisons.”</p><disp-quote content-type="editor-comment"><p>11. For the multiple comparison correction method, why did the authors choose permutation and did not use FDR or FWE provided by SPM? And why did they combine it with an uncorrected threshold? Similarly, the authors state &quot;corrections for autocorrelations were performed&quot; (line 216); could the authors expand on how this was done?</p></disp-quote><p>We thank the reviewer for this comment. Previous research has shown that a family wise error rate of 5% is invalid for clusterwise inference of fMRI data as implemented in SPM and other tools, leading to inflated false-positive rates of up to 70% (Eklund, Nichols, and Knutsson, 2016). The authors propose to use a permutation-based cluster-based threshold together with an uncorrected voxel-based threshold. We have therefore followed this guideline to ensure a proper control for multiple comparisons.</p><p>A permutation-based cluster threshold combined with an uncorrected voxel-threshold was used since standard correction methods such as a family wise error rate of 5% may lead to elevated false-positive rates.(37)</p><p>37. Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proceedings of the national academy of sciences. 2016 Jul 12;113(28):7900-5.</p><p>The option of adjusting for spatial autocorrelations in the JuSpace toolbox computes partial spatial correlation coefficients by adjusting for local gray matter probabilities as estimated from the TPM.nii provided with SPM12 (Dukart et al., 2020). We clarified this in the respective methods section explaining the JuSpace analysis:</p><p>“Furthermore, adjustment for spatial autocorrelation was performed by computing partial correlation coefficients between fALFF and neurotransmitter maps adjusted for local gray matter probabilities estimated from the SPM12-provided TPM.nii.(38)”</p><p>38. Dukart J, Holiga S, Rullmann M, Lanzenberger R, Hawkins PCT, Mehta MA, Hesse S, Barthel H, Sabri O, Jech R, Eickhoff SB. JuSpace: A tool for spatial correlation analyses of magnetic resonance imaging data with nuclear imaging derived neurotransmitter maps. Hum Brain Mapp. 2021 Feb 15;42(3):555-566. doi: 10.1002/hbm.25244. Epub 2020 Oct 20.</p><disp-quote content-type="editor-comment"><p>Discussion:</p><p>12. Would suggest greater comment in the Discussion on the neuropsychological test analyses. Only a few outcomes showed a nominal relationship with the fALFF-NT coefficients.</p></disp-quote><p>We have now expanded the discussion as suggested by the reviewer:</p><p>“The strength of co-localization of fALFF with NET was correlated with verbal fluency and MMSE, both being impaired in patients with bvFTD.(4,59,60) Thereby, a stronger negative co-localization (i.e. lower fALFF in patients in high density regions in health) was moderately associated with decreased test performance. Similarly, a correlation between MMSE and NE plasma concentration has been previously reported in Alzheimer’s disease.(61) Combined, these findings point to a potentially more general role of norepinephrinergic neurotransmission in cognitive decline observed across different dementia syndromes. This interpretation is in line with the recently proposed role of the locus coeruleus, the source of norepinephrine in the brain, in regulating processes of learning, memory and attention.(62)”</p><p>59. Diehl J, Kurz A (2002): Frontotemporal dementia: patient characteristics, cognition, and behaviour. Int J Geriatr Psychiatry 17: 914–918.</p><p>60. Schroeter ML, Pawelke S, Bisenius S, Kynast J, Schuemberg K, Polyakova M, et al. (2018): A modified reading the mind in the eyes test predicts behavioral variant frontotemporal dementia better than executive function tests. Front Aging Neurosci 10: 11.</p><p>61. Pillet L-E, Taccola C, Cotoni J, Thiriez H, André K, Verpillot R (2020): Correlation between cognition and plasma noradrenaline level in Alzheimer’s disease: a potential new blood marker of disease evolution. Transl Psychiatry 10: 213.</p><p>62. Tsukahara, Jason S., and Randall W. Engle. &quot;Fluid intelligence and the locus coeruleus–norepinephrine system.&quot; Proceedings of the National Academy of Sciences 118.46 (2021): e2110630118.</p><disp-quote content-type="editor-comment"><p>13. Sample sizes for D2 and GABAA tracers are quite small (&lt;10) which the authors should explicitly mention in the limitations or replicate with larger-N datasets.</p></disp-quote><p>We thank the reviewer for this suggestion. Based on the first comment listed regarding the tracer for D2, we already repeated the analysis for D2 using a different tracer, resulting in a sample size of 55 subjects. Unfortunately, currently there are no average maps with a larger sample size available for GABAA. Therefore, we added the following limitation to the Discussion section:</p><p>“Similarly, the reliability of the co-localization analyses is partly limited by the number of healthy volunteers used to derive the respective neurotransmitter average maps.”</p><disp-quote content-type="editor-comment"><p>14. The authors motivate studying fALFF in the Introduction but I felt this thread was lost in the Discussion. I recommend the authors expand on (in the Discussion) why fALFF is an appropriate and relevant measure to study in bvFTD, especially in light of their findings.</p></disp-quote><p>We agree with the reviewer and have now added a more detailed paragraph about the usefulness of fALFF as an appropriate and relevant measure to study in bvFTD:</p><p>“Our findings support the notion of fALFF as useful marker for assessing bvFTD related decline in brain function. In line with previous literature in bvFTD, we observe fALFF reductions mainly in frontal and temporal lobes, but also in the parietal lobe.(13,14) These findings support the notion of fALFF being a useful marker of metabolic impairment.(6,9) Moreover, we found a clear association of fALFF with several neurotransmitter systems pointing to a selective neurotransmitter vulnerability in bvFTD, as suggested in previous research.(24,25) In particular, the co-localization of fALFF with NET was associated with Verbal Fluency and MMSE, suggesting the sensitivity of fALFF to reflect modality specific cognitive decline.”</p><disp-quote content-type="editor-comment"><p>15. Given the hypothesis that prion-like proteins spread on the underlying structural network, an interesting future direction for this work would be to study structural connectivity instead of GMV. Since the authors mention this hypothesis in the Introduction (line 127), I felt some Discussion on this subject would be of interest, perhaps by expanding the paragraph that starts at line 377?</p></disp-quote><p>We agree with this comment and therefore added the following sentences in the discussion:</p><p>“An interesting future direction might compose integration of structural connectivity as measured by diffusion tensor imaging. A study by Dopper and colleagues (2014) showed reduced fractional anisotropy in healthy individuals carrying mutations compared to non-carriers.(58) Given that there were structural connectivity differences even before disease onset, it would be of interest to re-examine structural connectivity differences between healthy controls and patients (i.e. after disease onset). Repeating the neurotransmitter analyses might facilitate understanding of the underlying disease mechanism.”</p><p>58. Dopper EGP, Rombouts SARB, Jiskoot LC, Heijer T den, Graaf JRA de, Koning I de, et al. (2014): Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology, vol. 83. pp e19–e26.</p><disp-quote content-type="editor-comment"><p>16. I recommend the authors give credit to previous studies that investigate the mRNA-protein density correlation. Some examples:</p><p>a. Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., … and Knudsen, G. M. (2017). A high-resolution in vivo atlas of the human brain's serotonin system. Journal of Neuroscience, 37(1), 120-128. (For findings regarding the serotonin system)</p><p>b. Nørgaard, M., Beliveau, V., Ganz, M., Svarer, C., Pinborg, L. H., Keller, S. H., … and Knudsen, G. M. (2021). A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors. NeuroImage, 232, 117878. (For findings regarding the GABAA system)</p><p>c. Hansen, J. Y., Markello, R. D., Tuominen, L., Nørgaard, M., Kuzmin, E., Palomero-Gallagher, N., … and Misic, B. (2022). Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain. Neuroimage, 264, 119671. (For showing generally low correspondence between receptor density and mRNA)</p><p>d. Rizzo, G., Veronese, M., Heckemann, R. A., Selvaraj, S., Howes, O. D., Hammers, A., … and Bertoldo, A. (2014). The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study. Journal of Cerebral Blood Flow and Metabolism, 34(5), 827. (To my knowledge, the first study to test the association between AHBA mRNA expression and imaging-derived receptor densities across the cortex.)</p></disp-quote><p>We thank the reviewer for this comment. We have now cited the sources of all neurotransmitter maps utilized in our study within the methods. More detailed information can be found in Table S2 in the supplement. We additionally cited the Rizzo reference together with their MENGA toolbox in the methods and the Hansen reference in the discussion:</p><p>“Similarly, a previous study found the correspondence between receptor density and mRNA expression to be low.(65)”</p></body></sub-article></article>